US20050019407A1 - Composite dosage forms - Google Patents

Composite dosage forms Download PDF

Info

Publication number
US20050019407A1
US20050019407A1 US10/476,529 US47652904A US2005019407A1 US 20050019407 A1 US20050019407 A1 US 20050019407A1 US 47652904 A US47652904 A US 47652904A US 2005019407 A1 US2005019407 A1 US 2005019407A1
Authority
US
United States
Prior art keywords
dosage form
portions
active ingredient
different
interface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/476,529
Other languages
English (en)
Inventor
Harry Sowden
Frank Bunick
Gerard McNally
Der-Yang Lee
Martin Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Consumer Inc
Original Assignee
McNeil PPC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/967,414 external-priority patent/US6742646B2/en
Priority claimed from US09/966,939 external-priority patent/US6837696B2/en
Priority claimed from US09/966,509 external-priority patent/US6767200B2/en
Priority claimed from US09/966,450 external-priority patent/US6982094B2/en
Priority claimed from US09/966,497 external-priority patent/US7122143B2/en
Application filed by McNeil PPC Inc filed Critical McNeil PPC Inc
Priority to US10/476,529 priority Critical patent/US20050019407A1/en
Assigned to MCNEIL-PPC, INC. reassignment MCNEIL-PPC, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LEE, DER-YANG, MCNALLY, GERARD P., THOMAS, MARTIN, BUNICK, FRANK J., SOWDEN, HARRY S.
Publication of US20050019407A1 publication Critical patent/US20050019407A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/02—Apparatus specially adapted for manufacture or treatment of sweetmeats or confectionery; Accessories therefor
    • A23G3/04—Sugar-cookers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G1/00—Cocoa; Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/30—Cocoa products, e.g. chocolate; Substitutes therefor
    • A23G1/50—Cocoa products, e.g. chocolate; Substitutes therefor characterised by shape, structure or physical form, e.g. products with an inedible support
    • A23G1/54—Composite products, e.g. layered laminated, coated, filled
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/0002—Processes of manufacture not relating to composition and compounding ingredients
    • A23G3/0004—Processes specially adapted for manufacture or treatment of sweetmeats or confectionery
    • A23G3/0019—Shaping of liquid, paste, powder; Manufacture of moulded articles, e.g. modelling, moulding, calendering
    • A23G3/0025—Processes in which the material is shaped at least partially in a mould in the hollows of a surface, a drum, an endless band, or by a drop-by-drop casting or dispensing of the material on a surface, e.g. injection moulding, transfer moulding
    • A23G3/0029—Moulding processes for hollow products, e.g. opened shell
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
    • A23G3/368—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/50—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by shape, structure or physical form, e.g. products with supported structure
    • A23G3/54—Composite products, e.g. layered, coated, filled
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/02—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space
    • B30B11/08—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses using a ram exerting pressure on the material in a moulding space co-operating with moulds carried by a turntable
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B15/00—Details of, or accessories for, presses; Auxiliary measures in connection with pressing
    • B30B15/30—Feeding material to presses
    • B30B15/302—Feeding material in particulate or plastic state to moulding presses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
    • Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]

Definitions

  • This invention relates to composite dosage forms such as pharmaceutical compositions. More particularly, this invention relates to composite dosage forms comprising at least one active ingredient and having a first portion comprising a first molded material and a second portion comprising a second material, in which the second material is compositionally different than the first material, surfaces of the first and second portions are joined at an interface, and the first portion surface at the interface resides substantially conformally upon the second portion surface at the interface.
  • Dosage forms having two or more distinct portions are useful in the pharmaceutical arts for overcoming a number of commonly encountered challenges, including the separation of incompatible active ingredients, achieving acceptable content uniformity of a low-dose/high potency active ingredient, delivering one or more active ingredients in a pulsatile manner, and providing unique aesthetic characteristics for dosage form identification.
  • Known methods for achieving a multi-portion pharmaceutical dosage form include particle coating, multi-layer tablets, compression-coating, and spray coating techniques. It is also known for example in the household products industry to assemble solid forms from two or more different parts for the purpose of separating active ingredients, or delivering different active ingredients at different times.
  • Dosage forms comprising coated particles are described for example in U.S. Pat. No. 5,593,696, which describes oral dosage forms for treating of gastric disorders.
  • the dosage forms contain, as active ingredients, famotidine and sucralfate.
  • the famotidine is present in the composition in particulate (granulate) form, and the particulate famotidine is provided with a protective barrier layer which prevents interaction between the famotidine and the sucralfate in the composition.
  • the barrier layer is preferably a polymeric coat which dissolves partially in vivo in the stomach environs to release the coated famotidine.
  • 5,980,944 describes a solid oral dosage form for the treatment of gastrointestinal disorders comprising a therapeutically effective amount of a pharmaceutical suitable for the treatment of gastric disorders selected from the group consisting of granules of diphenoxylate, loperamide, loperamide-N-oxide, pharmaceutically acceptable salts thereof and combinations thereof, and a therapeutically effective amount of simethicone wherein the pharmaceutical and simethicone are separated by a barrier coat on the granules which is substantially impermeable to simethicone.
  • a pharmaceutical suitable for the treatment of gastric disorders selected from the group consisting of granules of diphenoxylate, loperamide, loperamide-N-oxide, pharmaceutically acceptable salts thereof and combinations thereof
  • simethicone wherein the pharmaceutical and simethicone are separated by a barrier coat on the granules which is substantially impermeable to simethicone.
  • Multi-layer tablets are described, for example, in U.S. Pat. No. 5,200,193, which describes multi-layered pharmaceutical active tablets comprising an immediate release layer and a homogeneous compressed sustained release layer comprising an erosion promoter, which upon administration results in a long-lasting, slow and relatively regular incremental release of the pharmaceutical active ingredient.
  • U.S. Pat. No. 6,372,252 describes a pharmaceutical sustained release formulation capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.
  • the modified release guaifenesin bi-layer tablet disclosed has a first portion comprising an immediate release formulation of guaifenesin and a second portion comprising a sustained release formulation of guaifenesin.
  • U.S. Pat. No. 4,999,226 discloses a multi-layered tablet containing an ibuprofen layer, a piperidino-alkanol antihistamine layer, and a layer or layers containing conventional pharmaceutical excipients which is interspersed between the ibuprofen and piperidino-alkanol layer and serves to physically separate them.
  • This multi-layered tablet solves the problems associated with the physical and chemical incompatibilities between ibuprofen and the piperidinoalkanol antihistamines.
  • U.S. Pat. No. 4,198,390 describes a tablet containing at least two separate and discrete volume portions, one of which contains simethicone and the other of which contains antacid.
  • a barrier separates the two volume portions to maintain the simethicone out of contact with the antacid and to prevent migration of the simethicone from its volume portion of the tablet into the volume portion containing the antacid, and vice versa.
  • U.S. Pat. No. 5,133,892 describes a multilayer detergent tablet containing an outer layer, a barrier layer and an inner layer. The tablet sequentially releases ingredients contained in the outer layer and ingredients contained in the inner layer. The time interval between the release of the outer layer ingredients and the release of the inner layer ingredients is controlled by the particular choice of an ingredient for the barrier layer and the relative thicknesses of the inner layer, the barrier layer and the outer layer. The tablet is able to separate in time the dissolution of incompatible ingredients such as an enzyme and a chlorine bleach. The tablet also provides sequential release of a dishwashing composition and a rinse aid composition such that cleaning is accomplished prior to the release of the rinse aid.
  • Compression-coated tablets are useful for separation of incompatible active ingredients, and for pulsatile release of one or more active ingredients.
  • Compressed coatings may have shapes which are substantially independent of the shape of the core, as disclosed for example in WO 00/18447.
  • Commercially available compression coating machines are available for example from Korsch America Inc., a subsidiary of Korsch AG, and described in WO 89/11968.
  • Modified release dosage forms prepared via compression are exemplified in U.S. Pat. Nos. 5,738,874 and 6,294,200, and WO 99/51209. It is possible, via compression-coating, to produce a 2-portion shell, which may function as a barrier, or release delaying coating; however compression-coated systems are limited by the shell thickness and shell composition as well as processing costs.
  • the liquid, dissolved or suspended active substance can also be divided into discrete droplets of specific volume after application of a high pressure during passage through a narrow nozzle, whereby the individual droplets are successively charged electrically and are intermittently deflected electrostatically towards the pharmaceutical carriers.
  • molded portions comprising a mixture of compressed and molded portions are known for example for delivery of detergents.
  • WO 01/49815 describes a composition for use in a dishwasher characterized by a base composition in the form of a tablet which becomes active substantially during the main wash cycle, and at least one separate zone in or on the tablet is provided with a substance that becomes active substantially during the rinse cycle of the dishwasher.
  • One example of such assembled forms comprises a compressed tablet portion having a hemispherical indentation in a major face, and a molded spherical portion fit into and adhered to the indentation in the compressed portion.
  • the molded portion may be smaller than the indentation in the compressed portion, e.g. the diameter of the molded portion is at least about 20 microns less that the diameter of the opening in the compressed portion.
  • similar forms may be assembled by press-fitting. In these forms the dimensions of the molded portion and the opening in the compressed portion may be similar.
  • Such assemblies are additionally limited in the types of geometries that are possible at the interface. In press-fit assemblies, the width of the molded portion at the deepest part of the interface may not be substantially larger than the width of the opening through which it must be fit. In other words the draft angle between the outer and inner surfaces of the compressed portion may not be negative. Moreover, the interface or area of contact between the two portions may not form an interlock.
  • Intagliations are impressed marks typically achieved by engraving or impressing of a graphical representation, for example a figure, mark, character, symbol such as a letter, a name, a logo, a pictoral representation, and the like, or any combination thereof, in a tablet or other solid dosage form, preferably by a punching procedure.
  • a graphical representation for example a figure, mark, character, symbol such as a letter, a name, a logo, a pictoral representation, and the like, or any combination thereof, in a tablet or other solid dosage form, preferably by a punching procedure.
  • U.S. Pat. No. 5,827,535 describes soft gelatin capsules having an external surface having defined thereon an impressed graphical representation.
  • 5,405,642 discloses a method of highlighting intagliations in white or colored coated tablets by spraying onto said tablets a suspension comprising a filling material having a different color, a waxy material and a solvent, and removing the solvent and the excess of filling material and waxy material.
  • the suspension of U.S. Pat. No. 5,405,642 comprises a waxy material and a filling material in a critical weight ratio from about 1:3 to about 1:12. Too little waxy material will lead to insufficient bonding of the filling material; too much waxy material the filling material will bond too strongly to the tablet surface and consequently will be difficult to remove afterwards. Suitable solvents for the suspension of U.S. Pat. No.
  • 5,405,642 are those solvents wherein the filling material and, if present, the dye, do not dissolve.
  • non-dyed starches and celluloses may be suspended in alcohols, e.g. ethanol, isopropanol and the like, halogenated hydrocarbons, e.g. dichloromethane, trichloromethane and the like.
  • EP 060,023 discloses a method of emphasizing intagliations in colored (i.e. not white) solid articles, in particular tablets, by coating the tablet surface and filling up the intagliations with a coating film comprising an optically anisotropic substance.
  • EP 088,556 relates to a method of highlighting intagliations in white or colored tablets by contacting said tablets with a dry, powdery material having a different color than the tablet surface and then removing the excess powdery material not deposited in the intagliations.
  • the powdery material is thought to adhere better to the intagliations of coated tablets than to those of uncoated tablets. Adherence can further be increased by using a mixture of a wax and a powdery material as the deposition material and heating the filled tablets to 40° C.-90° C. to melt the wax. Finally, an outer coating may be applied to the filled tablets.
  • the method disclosed in EP 088,556 has several problems.
  • U.S. Pat. No. 4,139,589 describes a process for the manufacture of an inlaid tablet, comprising the steps of incorporating into a plastic chewing gum mass a sustained-release active ingredient; incorporating into a non-plastic tablet mass a substantially immediate-release pharmaceutically active ingredient; and respectively converting the chewing gum mass and the tablet mass into the core and the outer layer of the inlaid tablet.
  • a preferred embodiment includes converting the tablet mass into a recessed preformed element, converting the chewing gum mass into the core, inserting the core into the recess of the preformed element, introducing the preformed element and the core into a tablet mold, and subjecting the preformed element and the core in the mold to pressure.
  • molded portions into delivery systems, has been used in the household products industry to achieve an additional degree of versatility.
  • Assembled forms comprising a mixture of compressed and molded portions are known, for example, for delivery of detergents.
  • WO 01/49815 describes a composition for use in a dishwasher characterized by a base composition in the form of a tablet which becomes active substantially during the main wash cycle, and at least one separate zone in or on the tablet is provided with a substance that becomes active substantially during the rinse cycle of the dishwasher.
  • One example of such assembled forms comprises a compressed tablet portion having a hemispherical indentation in a major face, and a molded spherical portion fit into and adhered to the indentation in the compressed portion.
  • the molded portion may be smaller than the indentation in the compressed portion, e.g. the diameter of the molded portion is at least about 20 microns less that the diameter of the opening in the compressed portion.
  • similar forms may be assembled by press-fitting. In these forms the dimensions of the molded portion and the opening in the compressed portion may be similar.
  • Such assemblies are additionally limited in the types of geometries that are possible at the interface. In press-fit assemblies, the width of the molded portion at the deepest part of the interface may not be substantially larger than the width of the opening through which it must be fit. In other words, the “draft angle” between the outer and inner surfaces of the compressed portion may not be negative. Moreover, the interface or area of contact between the two portions may not form an interlock.
  • a dosage form comprising at least one active ingredient and a first portion comprising a first molded material and a second portion comprising a second material, in which the second material is compositionally different than the first material, the first and second material are joined at an interface, and a surface of the first portion at the interface resides substantially conformally upon a surface of the second portion of the interface.
  • It is another object of this invention to provide a dosage form comprising at least one active ingredient, a first portion comprising a first molded material, a second portion comprising a second material which is compositionally different from the first material, and a third portion which is located between the first and second portions.
  • Dosage forms of the present invention advantageously have enhanced versatility for a number of applications, including dosage forms to deliver pharmaceuticals, nutritionals and/or confections, which may offer benefits of improved swallowability for an irregularly shaped substrate, or unique and pleasant aesthetic qualities that are valuable in the marketplace.
  • the dosage form of the present invention also advantageously provides a cost-effective means for ensuring acceptable content uniformity, and improved safety of handling for low-dose/high potency active ingredients.
  • Low dose active ingredients can be homogeneously dispersed in the molded portion when it is in a flowable state. This eliminates problems associated with powder segregation in blends for tableting, and minimizes exposure of workers to potential inhalation of dust containing the high potency active ingredient.
  • the dosage form of this invention comprises at least one active ingredient, a first portion comprising a first molded material and a second portion comprising a second material which is compositionally different than the first material.
  • the second material may be a compressed material such as a compressed powder.
  • the first portion comprises a thermoplastic material.
  • the first molded material is substantially free of pores having a diameter of 0.5 to 5.0 microns.
  • the first portion comprises a foam.
  • the first portion comprises an aerated material.
  • the active ingredient is coated with a release-modifying coating.
  • first and second portions are in substantial contact at the interface.
  • the interface is in the form of an abutment.
  • first and second portions overlap at the interface.
  • first and second portions interlock at the interface.
  • the first and second portions dissociate upon immersion in aqueous media.
  • the dosage form further comprises a third portion, which is located between the first and second portions.
  • the third portion comprises a chemical reaction product of the first and second materials.
  • the third portion is impermeable to one or more active ingredients contained in the dosage form.
  • the third portion is impermeable to water.
  • the third portion acts as a barrier to the passage therethrough of one or more active ingredients contained in the first or second portions.
  • the third portion functions to control the passage of one or more active ingredients contained in the first or second portions.
  • the third portion comprises openings which allow the passage of one or more active ingredients therethrough.
  • the third portion comprises a microelectronic device.
  • the first and second portions have different colors.
  • the first and second portions have different opacities.
  • the first and second portions have different solubilities in acidic, alkaline, or neutral aqueous media.
  • the first and second portions have different dissolution rates in acidic, alkaline, or neutral aqueous media.
  • the first and second portions have different disintegration times in acidic, alkaline, or neutral aqueous media.
  • first and second portions have different hydrophilicities.
  • the first and second portions have different topographies.
  • the first and second portions have different elasticities.
  • the first and second portions have different plasticities.
  • the first and second portions have different tensile strengths.
  • the first and second portions have different crystallinities.
  • first and second portions each comprise at least one active ingredient, and release active ingredient at different rates.
  • the first portion is obtained by injection molding.
  • the second portion is a substrate, and the first portion is formed directly upon the first portion.
  • the first portion comprises at least one active ingredient.
  • the second portion comprises at least one active ingredient.
  • first and the second portion each comprise at least one active ingredient which may be the same or different.
  • the first portion further comprises an insert.
  • the second portion further comprises an insert.
  • the insert is molded.
  • the first portion is contained within the second portion.
  • At least one active ingredient is capable of dissolution, and dissolution of the active ingredient meets USP specifications for immediate release tablets containing the active ingredient.
  • the second material is a compressed material.
  • either the first portion, the second portion or both comprises a microelectronic device.
  • a shell resides upon the outer surfaces of the first and second portions.
  • the surface of the first portion at the interface has indentations and protrusions corresponding substantially inversely to indentations and protrusions on the surface of the second portion at the interface.
  • indentations and protrusions have a length, width, height or depth greater than 10 microns.
  • the area of the interface surfaces is at least 50% of the area of a major face of either the first or second portion.
  • an entire face of the first portion is in substantial contact with the second portion.
  • an entire face of the second portion is in substantial contact with the first portion.
  • a side or face of the second portion comprises a cavity, and the first portion is in contact with the entire surface of the cavity.
  • At least one exterior surface of the first portion is flush with at least one exterior surface of the second portion.
  • FIGS. 1A and 1B are top and side views of an embodiment of this invention.
  • FIGS. 2A and 2B are top and side views of another embodiment of this invention.
  • FIGS. 3A and 3B are top and side views of another embodiment of this invention.
  • FIGS. 4A and 4B are top and side views of another embodiment of this invention.
  • FIGS. 5A and 5B are top and side views of another embodiment of this invention.
  • FIGS. 6A and 6B are top and side views of another embodiment of this invention.
  • FIGS. 7A-7C are top, side and exploded views of another embodiment of this invention.
  • FIGS. 8A-8C side views of other embodiments of this invention.
  • FIGS. 9A and 9B are top and side views of another embodiment of this invention.
  • FIG. 10 is a side view of another embodiment of this invention.
  • dosage form applies to any solid object, semi-solid, or liquid composition, designed to contain a specific pre-determined amount (i.e. dose) of a certain ingredient, for example an active ingredient as defined below.
  • Suitable dosage forms may be pharmaceutical drug delivery systems, including those for oral administration, buccal administration, rectal administration, topical, transdermal, or mucosal delivery, or subcutaneous implants, or other implanted drug delivery systems; or compositions for delivering minerals, vitamins and other nutraceuticals, oral care agents, flavorants, and the like.
  • the dosage forms of the present invention are considered to be solid, however they may contain liquid or semi-solid components.
  • the dosage form is an orally administered system for delivering a pharmaceutical active ingredient to the gastro-intestinal tract of a human.
  • the dosage form is an orally administered “placebo” system containing pharmaceutically inactive ingredients, and the dosage form is designed to have the same appearance as a particular pharmaceutically active dosage form, such as may be used for control purposes in clinical studies to test, for example, the safety and efficacy of a particular pharmaceutically active ingredient.
  • Suitable active ingredients for use in the dosage form of this invention include for example pharmaceuticals, minerals, vitamins and other nutraceuticals, oral care agents, flavorants and mixtures thereof.
  • Suitable pharmaceuticals include analgesics, anti-inflammatory agents, antiarthritics, anesthetics, antihistamines, antitussives, antibiotics, anti-infective agents, antivirals, anticoagulants, antidepressants, antidiabetic agents, antiemetics, anti flatulents, antifungal s, antispasmodics, appetite suppressants, bronchodilators, cardiovascular agents, central nervous system agents, central nervous system stimulants, decongestants, diuretics, expectorants, gastrointestinal agents, migraine preparations, motion sickness products, mucolytics, muscle relaxants, osteoporosis preparations, polydimethylsiloxanes, respiratory agents, sleep-aids, urinary tract agents and mixtures thereof.
  • Suitable oral care agents include breath fresheners, tooth whiteners, antimicrobial agents, tooth mineralizers, tooth decay inhibitors, topical anesthetics, mucoprotectants, and the like.
  • Suitable flavorants include menthol, peppermint, mint flavors, fruit flavors, chocolate, vanilla, bubblegum flavors, coffee flavors, liqueur flavors and combinations and the like.
  • Suitable gastrointestinal agents include antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum sodium carbonate; stimulant laxatives, such as bisacodyl, cascara sagrada, danthron, senna, phenolphthalein, aloe, castor oil, ricinoleic acid, and dehydrocholic acid, and mixtures thereof; H2 receptor antagonists, such as famotadine, ranitidine, cimetadine, nizatidine; proton pump inhibitors such as omeprazole or lansoprazole; gastrointestinal cytoprotectives, such as sucraflate and misoprostol; gastrointestinal prokinetics, such as prucalopride, antibiotics for H.
  • antacids such as calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, aluminum hydroxide, sodium bicarbonate, dihydroxyaluminum
  • pylori such as clarithromycin, amoxicillin, tetracycline, and metronidazole; antidiarrheals, such as diphenoxylate and loperamide; glycopyrrolate; antiemetics, such as ondansetron, analgesics, such as mesalamine.
  • the active agent may be selected from bisacodyl, famotadine, ranitidine, cimetidine, prucalopride, diphenoxylate, loperamide, lactase, mesalamine, bismuth, antacids, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • the active agent is selected from analgesics, anti-inflammatories, and antipyretics, e.g. non-steroidal anti-inflammatory drugs (NSAIDs), including propionic acid derivatives, e.g. ibuprofen, naproxen, ketoprofen and the like; acetic acid derivatives, e.g. indomethacin, diclofenac, sulindac, tolmetin, and the like; fenamic acid derivatives, e.g. mefanamic acid, meclofenamic acid, flufenamic acid, and the like; biphenylcarbodylic acid derivatives, e.g.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • the active agent is selected from propionic acid derivative NSAID, e.g. ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof.
  • NSAID e.g. ibuprofen, naproxen, flurbiprofen, fenbufen, fenoprofen, indoprofen, ketoprofen, fluprofen, pirprofen, carprofen, oxaprozin, pranoprofen, suprofen, and pharmaceutically acceptable salts, derivatives, and combinations thereof.
  • the active agent may be selected from acetaminophen, acetyl salicylic acid, ibuprofen, naproxen, ketoprofen, flurbiprofen, diclofenac, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • the active agent may be selected from pseudoephedrine, phenylpropanolamine, chlorpheniramine, dextromethorphan, diphenhydramine, astemizole, terfenadine, fexofenadine, loratadine, desloratidine, doxilamine, norastemizole, cetirizine, mixtures thereof and pharmaceutically acceptable salts, esters, isomers, and mixtures thereof.
  • Suitable polydimethylsiloxanes which include, but are not limited to dimethicone and simethicone, are those disclosed in U.S. Pat. Nos. 4,906,478, 5,275,822, and 6,103,260, the contents of each is expressly incorporated herein by reference.
  • simethicone refers to the broader class of polydimethylsiloxanes, including but not limited to simethicone and dimethicone.
  • the active ingredient or ingredients are present in the dosage form in a therapeutically effective amount, which is an amount that produces the desired therapeutic response upon oral administration and can be readily determined by one skilled in the art. In determining such amounts, the particular active ingredient being administered, the bioavailability characteristics of the active ingredient, the dose regime, the age and weight of the patient, and other factors must be considered, as known in the art.
  • the first or second portion comprises at least about 85 weight percent of the active ingredient.
  • the active ingredient may be coated with a taste masking coating, as known in the art.
  • suitable taste masking coatings are described in U.S. Pat. No. 4,851,226, U.S. Pat. No. 5,075,114, and U.S. Pat. No. 5,489,436.
  • Commercially available taste masked active ingredients may also be employed.
  • acetaminophen particles which are encapsulated with ethylcellulose or other polymers by a coaccervation process may be used in the present invention. Coaccervation-encapsulated acetaminophen may be purchased commercially from Eurand America, Inc. (Vandalia, Ohio) or from Circa Inc., (Dayton, Ohio).
  • At least a portion of the active ingredient may be optionally coated with a release-modifying coating, as known in the art.
  • a release-modifying coating as known in the art.
  • suitable release modifying coatings are described, for example, U.S. Pat. Nos. 4,173,626; 4,863,742; 4,980,170; 4,984,240; 5,286,497; 5,912,013; 6,270,805; and 6,322,819.
  • Commercially available modified release coated active particles may also be employed. Accordingly, all or a portion of one or more active ingredients may be coated with a release-modifying material.
  • the active ingredient or ingredients may be present in the dosage form in any form.
  • the active ingredient may be dispersed at the molecular level, e.g. melted or dissolved, within the dosage form, or may be in the form of particles, which in turn may be coated or uncoated.
  • the particles typically have an average particle size of about 1-2000 microns. In one preferred embodiment, such particles are crystals having an average particle size of about 1-300 microns. In another preferred embodiment, the particles are granules or pellets having an average particle size of about 50-2000 microns, preferably about 50-1000 microns, most preferably about 100-800 microns.
  • the first portion of the dosage form is prepared by molding.
  • the first portion may have any shape that can be molded, and has an area of its surface that is in contact with the second portion of the dosage form.
  • a substantial proportion of the surface area of one entire face of the first molded portion has a shape which is defined by the shape of the second portion.
  • the second portion of the dosage form may be prepared by any suitable method, for example it may be molded or compressed. In one embodiment, the second portion has one or more major faces. If the second portion is molded, it may have any shape that can be molded.
  • Molded shapes which may be used for the first portion or second portion (if molded) include a truncated cone; a polyhedron, such as a cube, pyramid, prism, or the like; or a shape having the geometry of a space figure with some non-flat faces, such as a cone, cylinder, sphere, torus, or the like.
  • Suitable shapes for compressed dosage forms include tablet shapes formed from compression tooling shapes described by “The Elizabeth Companies Tablet Design Training Manual” (Elizabeth Carbide Die Co., Inc., p.7 (McKeesport, Pa.) (incorporated herein by reference) as follows (the tablet shape corresponds inversely to the shape of the compression tooling):
  • the surface of one or more faces of the second portion may be substantially smooth, i.e. may have indentations or protrusions only at the microscopic level on the order of less than about 20 microns in width, depth, or height.
  • the surface of one or more faces the second portion may be textured, i.e. having indentations or protrusions greater than about 20 microns, e.g. greater than about 50 microns, or greater than about 100 microns, or from about 1000 microns to about 30,000 microns in width, depth, or height.
  • the surface may contain an embossed (raised) or debossed (indented) design.
  • the surface of one or more faces the second portion may contain indentations, intagliations, letters, symbols or a pattern such as a graphic or logo.
  • one or more faces of the second portion may contain one or more depressions covering a substantial proportion of its surface area, for example at least about 10%, or at least about 20% or at least about 30% or at least about 50% of the surface area of the face.
  • WO 01/85437 describes a process for the production of tablets with a cavity using a press.
  • WO 99/6157 describes tablets, compressed from a particulate material, having cavities to receive an additional ingredient or mix of ingredients.
  • a surface of the first molded portion resides substantially conformally upon a surface of the second portion.
  • substantially conformally means that a surface of the first molded portion substantially conforms inversely to the shape and texture of a surface of the second portion, such that the first and second portions are in substantial contact at the interface between them.
  • substantially contact means that a major portion of the surface area of at least one surface of the first portion is in contact with a major portion of the surface area of at least one surface of the second portion.
  • the dosage form of the invention may also incorporate pharmaceutically acceptable adjuvants, including, for example, preservatives, sweeteners such as aspartame, acesulfame potassium, sucralose, and saccharin; flavors, antioxidants, surfactants, and coloring agents.
  • pharmaceutically acceptable adjuvants including, for example, preservatives, sweeteners such as aspartame, acesulfame potassium, sucralose, and saccharin; flavors, antioxidants, surfactants, and coloring agents.
  • the dissolution characteristics of at least one active ingredient meets USP specifications for immediate release tablets containing the active ingredient.
  • the active ingredient or ingredients are preferably capable of dissolution upon contact with a fluid such as water, gastric fluid, intestinal fluid or the like.
  • USP 24 specifies that in pH 5.8 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the acetaminophen contained in the dosage form is released therefrom within 30 minutes after dosing, and for ibuprofen tablets, USP 24 specifies that in pH 7.2 phosphate buffer, using USP apparatus 2 (paddles) at 50 rpm, at least 80% of the ibuprofen contained in the dosage form is released therefrom within 60 minutes after dosing. See USP 24, 2000 Version, 19-20 and 856 (1999).
  • the dissolution characteristics of at least one active ingredient are modified: e.g.
  • one portion of the dosage form provides for immediate release of a first dose of an active ingredient therefrom, and the other portion of the dosage form provides for modified release of a second dose of either the same or a different active ingredient contained therein.
  • the first portion of the dosage form of this invention comprises a molded material.
  • the molded material may be obtained from flowable material.
  • the flowable material may be any edible material that is flowable at a temperature between about 37° C. and 250° C., and that is solid or can form a gel at a temperature between about ⁇ 10° C. and about 35° C.
  • the flowable material may comprise a dissolved or molten component, and a solvent such as for example water.
  • the solvent may be partially or substantially removed by drying.
  • Suitable flowable materials include those comprising film forming polymers, gelling polymers, hydrocolloids, low melting hydrophobic materials such as fats and waxes, non-crystallizable carbohydrates, and the like.
  • the flowable material comprises gelatin.
  • Gelatin is a natural, thermogelling polymer. It is a tasteless and colorless mixture of derived proteins of the albuminous class which is ordinarily soluble in warm water.
  • Type A gelatin is a derivative of acid-treated raw materials.
  • Type B gelatin is a derivative of alkali-treated raw materials. The moisture content of gelatin, as well as its Bloom strength, composition and original gelatin processing conditions, determine its transition temperature between liquid and solid. Bloom is a standard measure of the strength of a gelatin gel, and is roughly correlated with molecular weight.
  • Bloom is defined as the weight in grams required to move a half-inch diameter plastic plunger 4 mm into a 6.67% gelatin gel that has been held at 10° C. for 17 hours.
  • the flowable material is an aqueous solution comprising 20% 275 Bloom pork skin gelatin, 20% 250 Bloom Bone Gelatin, and approximately 60% water.
  • sucrose-fatty acid esters may comprise sucrose-fatty acid esters; fats such as cocoa butter, hydrogenated vegetable oil such as palm kernel oil, cottonseed oil, sunflower oil, and soybean oil; mono- di- and triglycerides, phospholipids, waxes such as carnuba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; sugar in the form on an amorphous glass such as that used to make hard candy forms, crystallized sugar in a supersaturated solution such as that used to make fondant forms; carbohydrates such as sugar-alcohols (for example, sorbitol, maltitol, mannitol, xylitol), or thermoplastic starch; and low-moisture polymer solutions such as mixtures of gelatin and other hydrocolloids at water contents up to about 30%, such as for example those used to make “gummi” confection forms.
  • the flowable material may comprise a film former such as a cellulose ether, e.g. hydroxypropylmethylcellulose or a modified starch, e.g. waxy maize starch; optionally an extender, such as polycarbohydrates, e.g. polydextrose or maltodextrin; optionally a thickener, such as a hydrocolloid, e.g. xanthan gum or carrageenan, or a sugar, e.g. sucrose; optionally a plasticizer, e.g. polyethylene glycol, propylene glycol, vegetable oils such as castor oil, glycerin, and mixtures thereof.
  • a film former such as a cellulose ether, e.g. hydroxypropylmethylcellulose or a modified starch, e.g. waxy maize starch
  • an extender such as polycarbohydrates, e.g. polydextrose or maltodextrin
  • a thickener such as
  • any film former known in the art is suitable for use in the flowable shell material of the present invention.
  • suitable film formers include, but are not limited to, polyvinylalcohol (PVA), polyvinylpyrrolidone (PVP), hydroxypropyl starch, hydroxyethyl starch, pullulan, methylethyl starch, carboxymethyl starch, methylcellulose, hydroxypropylcellulose (HPC), hydroxyethylmethylcellulose (HEMC), hydroxypropylmethylcellulose (HPMC), hydroxybutylmethylcellulose (HBMC), hydroxyethylethylcellulose (HEEC), hydroxyethylhydroxypropylmethyl cellulose (HEMPMC), methacrylic acid and methacrylate ester copolymers, polyethylene oxide and polyvinylpyrrolidone copolymers, gelatin, proteins such as whey protein, coaggulatable proteins such as albumin, casein, and casein isolates, soy protein and soy protein isolates, pre
  • HPMC 2910 is a cellulose ether having a degree of substitution of about 1.9 and a hydroxypropyl molar substitution of 0.23, and containing, based upon the total weight of the compound, from about 29% to about 30% methoxyl and from about 7% to about 12% hydroxylpropyl groups.
  • HPMC 2910 is commercially available from the Dow Chemical Company under the tradename METHOCEL E.
  • METHOCEL E5 which is one grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 4 to 6 cps (4 to 6 millipascal-seconds) at 20° C.
  • METHOCEL E6 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 5 to 7 cps (5 to 7 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer.
  • METHOCEL E15 which is another grade of HPMC-2910 suitable for use in the present invention, has a viscosity of about 15000 cps (15 millipascal-seconds) at 20° C. in a 2% aqueous solution as determined by a Ubbelohde viscometer.
  • degree of substitution shall mean the average number of substituent groups attached to a anhydroglucose ring
  • hydroxypropyl molar substitution shall mean the number of moles of hydroxypropyl per mole anhydroglucose.
  • modified starches include starches that have been modified by crosslinking, chemically modified for improved stability, or physically modified for improved solubility properties.
  • pre-gelatinized starches or “instantized starches” refers to modified starches that have been pre-wetted, then dried to enhance their cold-water solubility.
  • Suitable modified starches are commercially available from several suppliers such as, for example, A. E. Staley Manufacturing Company, and National Starch & Chemical Company.
  • One suitable modified starch includes the pre-gelatinized waxy maize derivative starches that are commercially available from National Starch & Chemical Company under the tradenames PURITY GUM and FILMSET, and derivatives, copolymers, and mixtures thereof.
  • Such waxy maize starches typically contain, based upon the total weight of the starch, from about 0 percent to about 18 percent of amylose and from about 100% to about 88% of amylopectin.
  • Suitable tapioca dextrins include those available from National Starch & Chemical Company under the tradename CRYSTAL GUM or K-4484, and derivatives thereof such as modified food starch derived from tapioca, which is available from National Starch and Chemical under the tradename PURITY GUM 40, and copolymers and mixtures thereof.
  • any thickener known in the art is suitable for use in the film forming composition of the present invention.
  • thickeners include but are not limited to hydrocolloids (also referred to herein as gelling polymers) such as alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gellan, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, and derivatives and mixtures thereof.
  • Additional suitable thickeners include crystallizable sugars, such as glucose (dextrose), fructose, and the like, and derivatives and combinations thereof.
  • Suitable xanthan gums include those available from C. P. Kelco Company under the tradename, KELTROL 1000, XANTROL 180, or K9B310.
  • plasticizer known in the pharmaceutical art is suitable for use in the present invention, and may include, but not be limited to polyethylene glycol; glycerin; sorbitol; triethyl citrate; tribuyl citrate; dibutyl sebecate; vegetable oils such as castor oil; surfactants such as polysorbates, sodium lauryl sulfates, and dioctyl-sodium sulfosuccinates; propylene glycol; mono acetate of glycerol; diacetate of glycerol; triacetate of glycerol; natural gums and mixtures thereof.
  • an optional plasticizer may be present in an amount, based upon the total weight of the solution, from about 0% to about 40%.
  • the flowable material may optionally comprise adjuvants or excipients, in which may comprise up to about 20% by weight of the flowable material.
  • suitable adjuvants or excipients include detackifiers, humectants, surfactants, anti-foaming agents, colorants, flavorants, sweeteners, opacifiers, and the like.
  • the flowable material comprises less than 5% humectants, or alternately is substantially free of humectants, such as glycerin, sorbitol, maltitol, xylitol, or propylene glycol.
  • Humectants have traditionally been included in pre-formed films employed in enrobing processes, such as that disclosed in U.S.
  • Humectants function by binding water and retaining it in the film.
  • Pre-formed films used in enrobing processes can typically comprise up to 45% water.
  • the presence of humectant prolongs the drying process, and can adversely affect the stability of the finished dosage form.
  • the molded material comprises at least about 80%; e.g. at least about 90% of a material selected from film formers, gelling polymers (hydrocolloids), low-melting hydrophobic materials, non-crystallizable carbohydrates, and mixtures thereof.
  • the molded material may be formed by injection molding, advantageously minimizing or eliminating the need for direct-compression filler-binders such as microcrystalline cellulose, spray-dried lactose, mineral salts such as calcium phosphate, crystalline sugars such as sucrose, dextrates and the like. These materials would disadvantageously detract from the clarity and stability of the molded material.
  • the molded material comprises less than about 10%, e.g. less than about 1%, or less than about 0.1% of direct-compression filler-binders.
  • the molded material is prepared by thermal setting molding using the method and apparatus described in copending U.S. patent application Ser. No. 09/966,450, pages 57-63, the disclosure of which is incorporated herein by reference.
  • the molded material is formed by injecting a starting material in flowable form into a molding chamber.
  • the starting material preferably comprises an active ingredient and a thermal setting material at a temperature above the melting point of the thermal setting material but below the decomposition temperature of the active ingredient.
  • the starting material is cooled and solidifies in the molding chamber into a shaped form (i.e. having the shape of the mold).
  • the molded material is prepared by thermal cycle molding using the method and apparatus described in copending U.S. patent application Ser. No. 09/966,497, pages 27-51, the disclosure of which is incorporated herein by reference.
  • the molded material is formed by injecting a starting material in flowable form into a heated molding chamber.
  • the starting material preferably comprises an active ingredient and a thermoplastic material at a temperature above the set temperature of the thermoplastic material but below the decomposition temperature of the active ingredient.
  • the starting material is cooled and solidifies in the molding chamber into a shaped form (i.e., having the shape of the mold).
  • the starting material must be in flowable form.
  • it may comprise solid particles suspended in a molten matrix, for example a polymer matrix.
  • the starting material may be completely molten or in the form of a paste.
  • the starting material may comprise an active ingredient dissolved in a molten material.
  • the starting material may be made by dissolving a solid in a solvent, which solvent is then evaporated from the starting material after it has been molded.
  • the starting material may comprise any edible material which is desirable to incorporate into a shaped form, including active ingredients such as those active ingredients described herein, nutritionals, vitamins, minerals, flavors, sweeteners, and the like.
  • the starting material comprises an active ingredient and a thermal setting material.
  • the thermal setting material may be any edible material that is flowable at a temperature between about 37 to about 250° C., and that is a solid at a temperature between about 0 to about ⁇ 10° C.
  • Preferred thermal setting materials include water-soluble polymers such as polyalkylene glycols, polyethylene oxides and derivatives, and sucrose esters; fats such as cocoa butter, hydrogenated vegetable oil such as palm kernel oil, cottonseed oil, sunflower oil, and soybean oil; mono- di- and triglycerides, phospholipids, waxes such as carnuba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, microcrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate; sugar in the form on an amorphous glass such as that used to make hard candy forms, crystallized carbohydrates in a supersaturated solution such as that used to make fondant forms; low-moisture polymer solutions such as mixtures of gelatin and other hydrocolloids at water contents up to about 30% such as those used to make “gummi” confection forms.
  • the thermal setting material is a water-soluble polymer such as polyethylene glycol.
  • the first portion may be made in any shape or size. For instance, irregularly shaped first portions may be made; i.e. shapes having no more than one axis of symmetry. Cylindrically shaped first portions may also be made.
  • the molded material may be prepared by any molding method, such as injection molding. In a preferred embodiment, the molded material may be made using the thermal setting method and apparatus described herein. In another preferred embodiment of the invention, the molded material is prepared by thermal cycle molding as described herein.
  • the first molded material and second material of the dosage form of this invention are compositionally different.
  • compositionally different means having features that are readily distinguishable by qualitative or quantitative chemical analysis, physical testing, or visual observation.
  • the first and second materials may contain different ingredients, or different levels of the same ingredients, or the first and second materials may have different physical or chemical properties, different functional properties, or be visually distinct. Examples of physical or chemical properties that may be different include hydrophylicity, hydrophobicity, hygroscopicity, elasticity, plasticity, tensile strength, crystallinity, and density.
  • Examples of functional properties which may be different include rate and/or extent of dissolution of the material itself or of an active ingredient therefrom, rate of disintegration of the material, permeability to active ingredients, permeability to water or aqueous media, and the like.
  • Examples of visual distinctions include size, shape, topography, or other geometric features, color, hue, opacity, and gloss.
  • the second portion of the dosage form of this invention comprises a compressed material.
  • the second portion is obtained by compressing a powder.
  • the powder may preferably comprise an active ingredient and optionally contain various excipients, such as binders, disintegrants, lubricants, fillers, glidants and the like, as is conventional, or other particulate material of a medicinal or non-medicinal nature, such as inactive placebo blends for tableting, confectionery blends, and the like.
  • the compressed second portion comprises active ingredient, powdered wax (such as shellac wax, microcrystalline wax, polyethylene glycol, and the like), and optionally disintegrants and lubricants as are well known to those skilled in the art.
  • the second portion is obtained from a blend of powders having an average particle size of about 50 to about 500 microns.
  • the active ingredient has an average particle size of about 50 to about 500 microns.
  • at least one excipient has an average particle size of about 50 to about 500 microns.
  • a major excipient, i.e. and excipient comprising at least 50% by weight of the core has an average particle size of about 50 to about 500 microns. Particles in this size range are particularly useful for direct compression processes.
  • the second portion is a directly compressed tablet, made from a powder which is substantially free of water soluble polymeric binders and hydrated polymers.
  • This composition is advantageous for maintaining an immediate release dissolution profile, minimizing processing and material costs, and providing for optimal physical and chemical stability of the dosage form.
  • Suitable excipients for use in a compressed portion include fillers, binders, disintegrants, lubricants, glidants, and the like.
  • Suitable fillers include water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose, sugar-alcohols, which include mannitol, sorbitol, maltitol, xylitol, starch hydrolysates, which include dextrins, and maltodextrins, and the like, water insoluble plasticly deforming materials such as microcrystalline cellulose or other cellulosic derivatives, water-insoluble brittle fracture materials such as dicalcium phosphate, tricalcium phosphate and the like and mixtures thereof.
  • water-soluble compressible carbohydrates such as sugars, which include dextrose, sucrose, maltose, and lactose
  • sugar-alcohols which include mannitol, sorbitol, maltitol, xylitol
  • starch hydrolysates which include dextrins, and maltodextrins, and the like
  • Suitable binders include dry binders such as polyvinyl pyrrolidone, hydroxypropylmethylcellulose, and the like; wet binders such as water-soluble polymers, including hydrocolloids such as alginates, agar, guar gum, locust bean, carrageenan, tara, gum arabic, tragacanth, pectin, xanthan, gellan, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, whelan, rhamsan, zooglan, methylan, chitin, cyclodextrin, chitosan, polyvinyl pyrrolidone, cellulosics, starches, and the like; and derivatives and mixtures thereof.
  • dry binders such as polyvinyl pyrrolidone, hydroxypropylmethylcellulose, and the like
  • Suitable disintegrants include sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked carboxymethylcellulose, starches, microcrystalline cellulose, and the like.
  • Suitable lubricants include long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, and waxes.
  • Suitable glidants include colloidal silicon dioxide, and the like.
  • the second portion is prepared by the compression methods and apparatus described in copending U.S. application Ser. No. 09/966,509, pages 16-27, the disclosure of which is incorporated herein by reference.
  • the second portion is made using a rotary compression module comprising a fill zone, insertion zone, compression zone, ejection zone, and purge zone in a single apparatus having a double row die construction as shown in FIG. 6 of U.S. application Ser. No. 09/966,509.
  • the dies of the compression module are preferably filled using the assistance of a vacuum, with filters located in or near each die.
  • the purge zone of the compression module includes an optional powder recovery system to recover excess powder from the filters and return excess powder to the dies.
  • the first or second portions, or both may contain at least in part one or more inserts.
  • the inserts can be made in any shape or size. For instance, irregularly shaped inserts can be made; i.e. shapes having no more than one axis of symmetry. Cylindrically shaped inserts may also be made.
  • the insert may be prepared using conventional techniques such as panning, compression, or molding. In one embodiment, the insert is prepared using the thermal setting method and apparatus as described herein.
  • the insert or inserts may have an average diameter from about 100 to about 1000 microns. In another embodiment of this invention, the insert(s) may have an average diameter or thickness from about 10% to about 90% of the diameter or thickness of the dosage form, or portion thereof. In yet another embodiment of this invention, the first or second dosage form portion may comprise a plurality of inserts.
  • the first portion, second portion, or both may comprise a microelectronic device (e.g. an electronic “chip”) which may be used as an active component or to control, for example, the rate of release of active ingredients contained within the first and/or second portions or insert in response to an input signal.
  • a microelectronic device e.g. an electronic “chip”
  • Examples of such microelectronic devices are as follows:
  • the invention provides a dosage form comprising a thermal cycle molded first portion and a compressed powder second portion.
  • the invention provides a dosage form comprising an injection molded first portion and a compressed powder second portion.
  • only the first portion comprises one or more active ingredients.
  • only the second portion comprises one or more active ingredients.
  • only the insert or inserts comprise one or more active ingredients.
  • both the first and second portions comprise one or more active ingredients.
  • one or more of the first portion, second portion or the insert or inserts comprise one or more of the active ingredients.
  • the active ingredient or ingredients are preferably capable of dissolution upon contact with a fluid such as water, gastric fluid, intestinal fluid or the like.
  • the invention advantageously enables a system of dosage form design with the versatility to accomodate multiple different dosage amounts of medication in the same size tablet, yet be readily identifiable to patients and healthcare professionals in terms of its identity and strength.
  • a particular medication may be commercially available in several different strength dosage forms. It is possible to design, using the present invention, a series of dosage forms in which the second portion comprises active ingredient, and varies in size according to the amount of active ingredient contained therein.
  • the molded first portion of the dosage form may be substantially free of active ingredient, and may vary in size inversely according the the size of the first portion, such that the overall size of the dosage form remains constant for the different strengths of active ingredient contained therein.
  • the two portions of the dosage forms may be visually distinct.
  • the second portion of the dosage form may be colored and/or opaque, and the first portion of the dosage form may be colorless, transparent, semi-transparent or translucent, thus providing visual reinforcement to both healthcare professionals and patients as to the varying strengths of the available dosage forms.
  • FIGS. 1A and 1B An overall understanding of the dosage form of this invention may be obtained by reference to FIGS. 1A and 1B .
  • a dosage form 2 is depicted which comprises a first portion 8 comprising a molded material 10 and a second portion 4 comprising a compressed material 6 .
  • Material 10 and material 6 are compositionally different. It will be understood that the shapes of the first and second portions in FIGS. 1A and 1B are merely illustrative, and are not meant to limit this invention in any way.
  • FIGS. 2A and 2B Another embodiment of the invention is depicted in FIGS. 2A and 2B , in which a dosage form 22 is depicted which comprises a first portion 24 comprising a first molded material 26 and a second molded material 27 , and a second portion 28 comprising a compressed material 30 .
  • Materials 26 and 27 are each are compositionally different from material 30 . It will be understood that the shapes of the first and second portions in FIGS. 2A and 2B are merely illustrative, and are not meant to limit this invention in any way.
  • FIGS. 3A and 3B Another embodiment of the invention is depicted in FIGS. 3A and 3B , in which dosage form 32 is depicted which comprises a first portion 34 comprising a molded material 36 , and a second portion 38 (shown in dashed outline in FIG. 3A ) comprising a compressed material 40 .
  • Material 36 is compositionally different from material 40 . It will be understood that the shapes of the first and second portions in FIGS. 3A and 3B are merely illustrative, and are not meant to limit this invention in any way.
  • FIGS. 4A and 4B Another embodiment of the invention is depicted in FIGS. 4A and 4B , in which dosage form 42 is depicted which comprises a first portion 44 comprising a first molded material 46 , and a second portion 48 which is a molded insert which comprises a second molded material 50 .
  • Material 46 is compositionally different from material 50 . It will be understood that the shapes of the first and second portions in FIGS. 4A and 4B are merely illustrative, and are not meant to limit this invention in any way.
  • FIGS. 5A and 5B Another embodiment of the invention is depicted in FIGS. 5A and 5B , in which dosage form 52 is depicted which comprises a first portion 54 comprising a molded material 56 , and a second portion 58 comprising a compressed material 60 .
  • Material 56 is compositionally different from material 60 . It will be understood that the shapes of the first and second portions in FIGS. 5A and 5B are merely illustrative, and are not meant to limit this invention in any way.
  • FIGS. 6A and 6B Another embodiment of the invention is depicted in FIGS. 6A and 6B , in which dosage form 62 is depicted which comprises a first portion 64 comprising a molded material 66 , and a second portion 68 comprising a compressed material 70 .
  • Material 66 is compositionally different from material 70 . It will be understood that the shapes of the first and second portions in FIGS. 6A and 6B are merely illustrative, and are not meant to limit this invention in any way.
  • FIGS. 7A-7C Another embodiment of the invention is depicted in FIGS. 7A-7C , in which dosage form 72 is depicted which comprises a first portion 74 comprising a molded material 76 , and a second portion 78 comprising a compressed material 80 .
  • Material 76 is compositionally different from material 70 .
  • first portion 74 has projections 75 on one face thereof. It will be understood that the shapes of the first and second portions in FIGS. 7A-7C are merely illustrative, and are not meant to limit this invention in any way.
  • FIGS. 8A-8C Other embodiments of the invention are depicted in FIGS. 8A-8C .
  • dosage form 82 is depicted which comprises a first portion 84 comprising a molded material 86 , and a second portion 88 comprising a compressed material 90 .
  • Material 86 is compositionally different from material 90 .
  • dosage form 182 is depicted which comprises a first portion 184 comprising a molded material 186 , and a second portion 188 comprising a compressed material 190 .
  • Material 186 is compositionally different from material 190 .
  • first portion 184 has a tongue shaped portion 183 which interfaces with groove shaped portion 185 of second portion 188 .
  • FIG. 8A dosage form 82 is depicted which comprises a first portion 84 comprising a molded material 86 , and a second portion 88 comprising a compressed material 90 .
  • Material 86 is compositionally different from material 90 .
  • dosage form 182 is depicted which comprises
  • dosage form 282 is depicted which comprises a first portion 284 comprising a molded material 286 , and a second portion 288 comprising a compressed material 290 .
  • Material 286 is compositionally different from material 290 . It will be understood that the shapes of the first and second portions in FIGS. 8A-8C are merely illustrative, and are not meant to limit this invention in any way.
  • FIGS. 9A and 9B Another embodiment of the invention is depicted in FIGS. 9A and 9B , in which dosage form 92 is depicted which comprises a first portion 94 comprising a molded material 96 , and a second portion 98 comprising a compressed material 100 .
  • Material 96 is compositionally different from material 100 . It will be understood that the shapes of the first and second portions in FIGS. 9A and 9B are merely illustrative, and are not meant to limit this invention in any way.
  • dosage form 102 which comprises a first portion 104 comprising a molded material 106 , a second portion 108 comprising a compressed material 105 , and a third portion 107 which may comprise a molded or compressed material 109 , preferably a molded material.
  • Material 106 is compositionally different from material 105 .
  • Material 109 may be compositionally the same or different than materials 106 or 105 , although in the embodiment depicted in FIG. 10 each of materials 106 , 105 and 109 is compositionally different from each other.
  • either first portion 104 or second portion 108 or both contain an active ingredient.
  • Third portion 107 may act as a barrier to prevent the passage there through of either or both the active ingredients contained in first portion 104 or second portion 108 . It will be understood that the shapes of the first, second and third portions in FIG. 10 are merely illustrative, and are not meant to limit this invention in any way.
  • the third portion has one or more major faces.
  • the third portion may be prepared by any suitable method, for example it may be molded or compressed.
  • the third portion may have a variety of molded shapes, as described above with respect to the first and second portions.
  • the invention is a bi-layer tablet in which the second portion is a compressed layer, the first portion is a molded layer, and the interface between the compressed and molded portions is a major tablet face.
  • the first molded material is substantially free of pores having a diameter of 0.5-5.0 microns.
  • substantially free means that the first molded material has a pore volume of less than about 0.02 cc/g, preferably less than about 0.01 cc/g, more preferably less than about 0.005 cc/g, in the pore diameter range of 0.5 to 5.0 microns.
  • Typical compressed materials have pore volumes of more than about 0.02 cc/g in this pore diameter range.
  • the molded material contained in the second or third portion likewise is substantially free of pores having a diameter of 0.5 to 5.0 microns.
  • Pore volume, pore diameter and density may be determined using a Quantachrome Instruments PoreMaster 60 mercury intrusion porosimeter and associated computer software program known as “Porowin.” The procedure is documented in the Quantachrome Instruments PoreMaster Operation Manual.
  • the PoreMaster determines both pore volume and pore diameter of a solid or powder by forced intrusion of a non-wetting liquid (mercury), which involves evacuation of the sample in a sample cell (penetrometer), filling the cell with mercury to surround the sample with mercury, applying pressure to the sample cell by: (i) compressed air (up to 50 psi maximum); and (ii) a hydraulic (oil) pressure generator (up to 60000 psi maximum).
  • Intruded volume is measured by a change in the capacitance as mercury moves from outside the sample into its pores under applied pressure.
  • the samples remain in sealed packages or as received in the dessicator until analysis.
  • the vacuum pump is switched on, the mercury vapor cold trap is filled with liquid nitrogen, the compressed gas supply is regulated at 55 psi., and the instrument is turned on and allowed a warm up time of at least 30 minutes.
  • the empty penetrometer cell is assembled as described in the instrument manual and its weight is recorded. The cell is installed in the low pressure station and “evacuation and fill only” is selected from the analysis menu, and the following settings are employed:
  • the cell (filled with mercury) is then removed and weighed.
  • the cell is then emptied into the mercury reservoir, and two tablets from each sample are placed in the cell and the cell is reassembled.
  • the weight of the cell and sample are then recorded.
  • the cell is then installed in the low-pressure station, the low-pressure option is selected from the menu, and the following parameters are set:
  • the composite dosage form of the present invention may be coated with an overcoating or shell.
  • At least part of the first portion extends below or penetrates through a surface of the second portion to define a penetrated surface area of the second portion.
  • the area of the interface surfaces is substantially the same, preferably at least 90%, of the penetrated surface area.
  • the area of the interface surfaces is at least 10%, preferably 25%, more preferably at least 50%, say greater than 90% of the area of a major face of either the first or second portions.
  • one face or side of the second portion comprises a cavity, and the first portion is in contact with the entire surface of the cavity.
  • a particular advantage of the present invention is that either the first molded portion or second portion may be larger in cross-section (in at least one location) than the opening to the cavity within the second portion or first molded portion, respectively, which receives the first portion or second portion.
  • an insert must be no larger in cross-section than the opening of the cavity which receives the insert.
  • the first molded portion or a part thereof is received by a cavity located within the second portion.
  • the first molded portion forms a “tongue” which interlocks with the cavity or “groove” within the second portion. This may also be expressed in terms of the “draft angle” of the second portion.
  • the term “draft angle” refers to the angle defined by the side wall of the cavity and a line perpindicular to the face of the inserted (e.g. first) portion, as described for example in Rosato et al., Injection Molding Handbook , pp. 601-04, (2d ed. 1995), the disclosure of which is incorporated herein by reference.
  • the draft angle of the second portion may have a value less than zero.
  • the draft angle must have a zero or positive value.
  • At least one exterior surface of the first portion is flush with at least one exterior surface of the second portion.
  • Dosage forms of the invention are made in a continuous process using an apparatus comprising a thermal cycle molding module and a compression module linked in series via a transfer device as described at pages 14-16 of copending U.S. application Ser. No. 09/966,939, the disclosure of which is incorporated herein by reference.
  • the dosage forms have the structure shown in FIGS. 1A and 1B and comprise a first portion comprising a first molded material and a second portion comprising a second material that is compressed.
  • the first portions are made of a flowable material comprising the following ingredients: Weight Mg/ Tablet Trade Name Manufacturer % Tablet Polyethylene Carbowax ® Union Carbide 60.3 190 Glycol 3350 Corporation, Danbury, CT Croscarmellose Ac-Di-Sol ® FMC Corporation, 30.1 95 Sodium Newark, DE Pseudoephedrine BASF 9.5 30 Hydrochloride PharmaChemikalien Crystal GmbH & Co., Ludwigshafen/ Rhein.
  • the second portions are made of a dry blend comprising the following ingredients: acetaminophen USP (590 mg/tablet), synthetic wax X-2068 T20 (53 mg/tablet), sodium starch glycolate (EXPLOTAB) (13.9 mg/tablet), silicon dioxide (0.6 mg/tablet), and magnesium stearate NF (2.4 mg/tablet).
  • the dry blend is compressed into second portions on a compression module as described in copending U.S. application Ser. No. 09/966,509 at pages 16-27 (incorporated herein by reference).
  • the compression module is a double row, rotary apparatus, comprising a fill zone, insertion zone, compression zone, ejection zone, and purge zone as shown in FIG. 6 of U.S. application Ser. No. 09/966,509.
  • the dies of the compression module are filled using vacuum assistance, with mesh screen filters located in die wall ports of each die.
  • Second portions are transferred from the compression module to the thermal cycle molding module via a transfer device.
  • the transfer device has the structure shown as 300 in FIG. 3 of copending U.S. application Ser. No. 09/966,414, described at pages 51-57, incorporated herein by reference. It comprises a plurality of transfer units 304 attached in cantilever fashion to a belt 312 as shown in FIGS. 68 and 69 of copending U.S. application Ser. No. 09/966,414.
  • the transfer device rotates and operates in sync with the thermal cycle molding module and compression module to which it is coupled.
  • Transfer units 304 comprise retainers 330 for holding the second portions as they travel around the transfer device.
  • the thermal cycle molding module 200 comprises a rotor 202 around which a plurality of mold units 204 are disposed.
  • the thermal cycle molding module includes a reservoir 206 (see FIG. 4 of pending U.S. application Ser. No. 09/966,497) for holding the material for making the first portions in flowable form.
  • the thermal cycle molding module is provided with a temperature control system for rapidly heating and cooling the mold units.
  • FIGS. 55 and 56 of U.S. application Ser. No. 09/966,497 depict the temperature control system 600 .
  • the thermal cycle molding module has the specific configuration shown in FIG. 26A of copending U.S. application Ser. No. 09/966,497.
  • the thermal cycle molding module comprises center mold assemblies 212 and upper mold assemblies 214 as shown in FIG. 26C of copending U.S. application Ser. No. 09/966,497, which mate to form mold cavities.
  • Flowable material for making the first portions which is heated to a flowable state in reservoir 206 , is injected into the resulting mold cavities, which contain an empty space adjacent to the second portions. First portions form in the empty space.
  • the temperature of the flowable material is then decreased, hardening the flowable material into first portions joined to the compressed second portions.
  • the mold assemblies open and eject the dosage forms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mechanical Engineering (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Confectionery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
US10/476,529 2001-09-28 2002-09-28 Composite dosage forms Abandoned US20050019407A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/476,529 US20050019407A1 (en) 2001-09-28 2002-09-28 Composite dosage forms

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US09/967,414 US6742646B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms
US09/966,939 US6837696B2 (en) 2001-09-28 2001-09-28 Apparatus for manufacturing dosage forms
US09/966,509 US6767200B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms
US09/966,450 US6982094B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms
US09/966,497 US7122143B2 (en) 2001-09-28 2001-09-28 Methods for manufacturing dosage forms
PCT/US2002/031163 WO2003026627A1 (fr) 2001-09-28 2002-09-28 Formes pharmaceutiques composites
US10/476,529 US20050019407A1 (en) 2001-09-28 2002-09-28 Composite dosage forms

Related Parent Applications (5)

Application Number Title Priority Date Filing Date
US09/966,509 Continuation-In-Part US6767200B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms
US09/966,939 Continuation-In-Part US6837696B2 (en) 2001-09-28 2001-09-28 Apparatus for manufacturing dosage forms
US09/967,414 Continuation-In-Part US6742646B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms
US09/966,497 Continuation-In-Part US7122143B2 (en) 2001-09-28 2001-09-28 Methods for manufacturing dosage forms
US09/966,450 Continuation-In-Part US6982094B2 (en) 2001-09-28 2001-09-28 Systems, methods and apparatuses for manufacturing dosage forms

Publications (1)

Publication Number Publication Date
US20050019407A1 true US20050019407A1 (en) 2005-01-27

Family

ID=27542311

Family Applications (15)

Application Number Title Priority Date Filing Date
US10/476,529 Abandoned US20050019407A1 (en) 2001-09-28 2002-09-28 Composite dosage forms
US10/476,238 Abandoned US20040241236A1 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/484,485 Abandoned US20040241208A1 (en) 2001-09-28 2002-09-28 Fondant-based pharmaceutical composition
US10/476,514 Abandoned US20040170750A1 (en) 2001-09-28 2002-09-28 Edible composition and dosage form comprising an edible shell
US10/476,530 Expired - Fee Related US8545887B2 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/476,504 Abandoned US20040213848A1 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/477,334 Expired - Fee Related US7968120B2 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/432,488 Abandoned US20040062804A1 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/393,610 Abandoned US20030219484A1 (en) 2001-09-28 2003-03-21 Immediate release dosage form comprising shell having openings therein
US10/393,752 Expired - Fee Related US7635490B2 (en) 2001-09-28 2003-03-21 Modified release dosage form
US10/393,765 Abandoned US20040018327A1 (en) 2001-09-28 2003-03-21 Delayed release dosage forms
US10/393,871 Expired - Fee Related US7416738B2 (en) 2001-09-28 2003-03-21 Modified release dosage form
US10/393,638 Abandoned US20030232082A1 (en) 2001-09-28 2003-03-21 Modified release dosage forms
US12/049,628 Abandoned US20080305150A1 (en) 2001-09-28 2008-03-17 Polymer Composition And Dosage Forms Comprising The Same
US12/391,475 Expired - Fee Related US7972624B2 (en) 2001-09-28 2009-02-24 Method of manufacturing modified release dosage forms

Family Applications After (14)

Application Number Title Priority Date Filing Date
US10/476,238 Abandoned US20040241236A1 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/484,485 Abandoned US20040241208A1 (en) 2001-09-28 2002-09-28 Fondant-based pharmaceutical composition
US10/476,514 Abandoned US20040170750A1 (en) 2001-09-28 2002-09-28 Edible composition and dosage form comprising an edible shell
US10/476,530 Expired - Fee Related US8545887B2 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/476,504 Abandoned US20040213848A1 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/477,334 Expired - Fee Related US7968120B2 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/432,488 Abandoned US20040062804A1 (en) 2001-09-28 2002-09-28 Modified release dosage forms
US10/393,610 Abandoned US20030219484A1 (en) 2001-09-28 2003-03-21 Immediate release dosage form comprising shell having openings therein
US10/393,752 Expired - Fee Related US7635490B2 (en) 2001-09-28 2003-03-21 Modified release dosage form
US10/393,765 Abandoned US20040018327A1 (en) 2001-09-28 2003-03-21 Delayed release dosage forms
US10/393,871 Expired - Fee Related US7416738B2 (en) 2001-09-28 2003-03-21 Modified release dosage form
US10/393,638 Abandoned US20030232082A1 (en) 2001-09-28 2003-03-21 Modified release dosage forms
US12/049,628 Abandoned US20080305150A1 (en) 2001-09-28 2008-03-17 Polymer Composition And Dosage Forms Comprising The Same
US12/391,475 Expired - Fee Related US7972624B2 (en) 2001-09-28 2009-02-24 Method of manufacturing modified release dosage forms

Country Status (20)

Country Link
US (15) US20050019407A1 (fr)
EP (12) EP1429743A1 (fr)
JP (11) JP2005508326A (fr)
KR (11) KR20040045030A (fr)
CN (10) CN100364515C (fr)
AT (4) ATE476957T1 (fr)
AU (1) AU2002330164A1 (fr)
BR (11) BR0206061A (fr)
CA (12) CA2446759A1 (fr)
CO (1) CO5570655A2 (fr)
DE (4) DE60239945D1 (fr)
ES (3) ES2444549T3 (fr)
HK (1) HK1072902A1 (fr)
HU (1) HUP0401686A3 (fr)
MX (12) MXPA04002977A (fr)
NO (4) NO20032363L (fr)
NZ (3) NZ532097A (fr)
PL (1) PL369134A1 (fr)
PT (1) PT1429738E (fr)
WO (12) WO2003026629A2 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165777A1 (en) * 2004-05-21 2006-07-27 Lawrence Solomon Dosage forms contained within a capsule or sachet
US20080187581A1 (en) * 2005-03-16 2008-08-07 Subhash Pandurang Gore Delivery System For Mulitple Drugs
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20090112191A1 (en) * 2007-10-31 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20090110714A1 (en) * 2007-10-31 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20090112048A1 (en) * 2007-10-31 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20090112190A1 (en) * 2007-10-31 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20090192449A1 (en) * 2007-10-23 2009-07-30 Seacrete Llc, A Limited Liability Corporation Of The State Of Delaware Adaptive dispensation in a digestive tract
US20100016348A1 (en) * 2007-10-31 2010-01-21 Frank Bunick Orally disintegrative dosage form
US20100239668A1 (en) * 2006-06-19 2010-09-23 Kaplan Allan S Segmented pharmaceutical dosage forms
US20110014352A1 (en) * 2007-02-15 2011-01-20 Pascal Grenier Method and apparatus for producing a centred compression coated tablet
US20110071184A1 (en) * 2009-09-24 2011-03-24 Bunick Frank J Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US20110070304A1 (en) * 2009-09-24 2011-03-24 Kriksunov Leo B Manufacture of tablet having immediate release region and sustained release region
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20130292884A1 (en) * 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Method of manufacturing solid dosage form
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
JP2017500367A (ja) * 2013-12-23 2017-01-05 ウェン、シャオガンＷＥＮ， Ｘｉａｏｇｕａｎｇ 二層錠剤及びその調製法
US9789066B2 (en) 2014-01-10 2017-10-17 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
US20190076365A1 (en) * 2016-03-15 2019-03-14 Astellas Pharma Inc. Tablet
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Families Citing this family (286)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
EP1067910B1 (fr) * 1998-04-03 2004-05-26 Egalet A/S Composition a liberation controllee
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP2957281A1 (fr) 2001-09-21 2015-12-23 Egalet Ltd. Systeme de liberation a base de polymere
EP1429744A1 (fr) 2001-09-21 2004-06-23 Egalet A/S Systeme a liberation de polymere de morphine
CA2446759A1 (fr) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Formes pharmaceutiques a liberation modifiee
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
US7780987B2 (en) * 2002-02-21 2010-08-24 Biovail Laboratories International Srl Controlled release dosage forms
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7169450B2 (en) 2002-05-15 2007-01-30 Mcneil-Ppc, Inc. Enrobed core
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
AU2003302881A1 (en) * 2002-12-11 2004-06-30 Ranbaxy Laboratories Limited Coating composition for taste masking coating and methods for their application and use
GB0229258D0 (en) * 2002-12-16 2003-01-22 Boots Healthcare Int Ltd Medicinal compositions
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US20050220870A1 (en) * 2003-02-20 2005-10-06 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
WO2004084869A1 (fr) * 2003-03-26 2004-10-07 Egalet A/S Compositions matricielles pour administration controlee de substances medicamenteuses
US8877241B2 (en) * 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
DK1615626T3 (da) * 2003-04-24 2010-02-08 Jagotec Ag Tablet med farvet kerne
WO2004093843A1 (fr) 2003-04-24 2004-11-04 Jagotec Ag Comprime a action retardee et a geometrie de noyau definie
EP1633328A4 (fr) * 2003-05-29 2008-07-09 Glykon Technologies Group Llc Procede et composition d'administration stable et controlee d'acide (-)-hydroxycitrique
CA2529984C (fr) 2003-06-26 2012-09-25 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DK1648421T3 (en) 2003-07-24 2017-12-04 Glaxosmithkline Llc ORAL SOLUBLE MOVIES
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
CA2535398C (fr) 2003-08-12 2013-11-12 Advancis Pharmaceuticals Corporation Antibiotique, utilisation et formulation associees
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2005075826A (ja) * 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
CN102669810B (zh) 2003-11-07 2014-11-05 美国无烟烟草有限责任公司 烟草组合物
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
KR101323478B1 (ko) * 2004-03-10 2013-10-31 다이쇼 세이야꾸 가부시끼가이샤 수난용성 약물 배합 고형 제제
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US8383154B2 (en) * 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI356036B (en) * 2004-06-09 2012-01-11 Smithkline Beecham Corp Apparatus and method for pharmaceutical production
US20060002986A1 (en) * 2004-06-09 2006-01-05 Smithkline Beecham Corporation Pharmaceutical product
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8609198B2 (en) * 2004-07-21 2013-12-17 Hewlett-Packard Development Company, L.P. Pharmaceutical dose form with a patterned coating and method of making the same
CA2575006A1 (fr) * 2004-07-26 2006-02-02 E. Itzhak Lerner Formes posologiques avec comprime a noyau pellicule gastro-resistant
US7621734B2 (en) 2004-07-28 2009-11-24 Mars, Incorporated Apparatus and process for preparing confectionery having an inclusion therein using forming rolls and a forming pin
US20060024361A1 (en) * 2004-07-28 2006-02-02 Isa Odidi Disintegrant assisted controlled release technology
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
EP1639899A1 (fr) * 2004-08-23 2006-03-29 Friesland Brands B.V. Composition moussante, soluble/dispersable dans l'eau froide sous forme de poudre
US10624858B2 (en) * 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP1944007A3 (fr) * 2004-09-24 2008-07-23 BioProgress Technology Limited Améliorations supplémentaires dans le compactage et l'enrobage de poudre
EP1807040A1 (fr) * 2004-09-24 2007-07-18 BioProgress Technology Limited Nouvelles améliorations dans le compactage et l'enrobage de poudres
DK1799453T3 (da) * 2004-09-30 2012-12-17 Monosolrx Llc Flerlagsfilm med ensartet indhold
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8383159B2 (en) 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
US20060093560A1 (en) * 2004-10-29 2006-05-04 Jen-Chi Chen Immediate release film coating
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
ES2401434T3 (es) 2004-11-19 2013-04-19 Glaxosmithkline Llc Método para dispensar de manera individualizada productos de combinación de fármacos de dosis variable para la individualización de terapias
US7404708B2 (en) * 2004-12-07 2008-07-29 Mcneil-Ppc, Inc. System and process for providing at least one opening in dosage forms
US7530804B2 (en) * 2004-12-07 2009-05-12 Mcneil-Ppc, Inc. System and process for providing at least one opening in dosage forms
RU2401125C2 (ru) 2004-12-27 2010-10-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ стабилизации лекарственного средства против деменции
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
WO2006072577A1 (fr) * 2005-01-07 2006-07-13 Sandoz Ag Procede de preparation de granules comprenant de l’amoxicilline
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US9713592B2 (en) * 2005-04-06 2017-07-25 Mallinckrodt Llc Matrix-based pulse release pharmaceutical formulation
EA200702221A1 (ru) * 2005-04-12 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
DK1889198T3 (da) 2005-04-28 2015-02-09 Proteus Digital Health Inc Farma-informatiksystem
AU2006241771B2 (en) * 2005-04-28 2010-09-09 Eisai R & D Management Co., Ltd. Composition containing anti-dementia drug
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
EP1890558B1 (fr) * 2005-05-18 2011-02-16 Laboratoires Goemar Produits alimentaires contenant de la laminarine
EP1895989A2 (fr) * 2005-06-03 2008-03-12 Egalet A/S Systeme d'apport de medicaments destine a apporter des substances actives dispersees dans un milieu de dispersion
EP2474308A1 (fr) 2005-06-27 2012-07-11 Valeant International (Barbados) SRL Formulations pharmaceutiques contenant l'hydrobromure de bupropion
US20070009573A1 (en) * 2005-07-07 2007-01-11 L N K International Method of forming immediate release dosage form
US20070015834A1 (en) * 2005-07-18 2007-01-18 Moshe Flashner-Barak Formulations of fenofibrate containing PEG/Poloxamer
DE102005034043B4 (de) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
JP2009504779A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における慢性腎不全及びその他の病気の治療：組成物及び方法
TWI274889B (en) * 2005-10-06 2007-03-01 Elan Microelectronics Corp Resistive touch screen measurement system
CN101374507A (zh) * 2005-10-14 2009-02-25 H.隆德贝克有限公司 含有依他普仑和安非他酮的稳定药物制剂
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007086846A1 (fr) * 2006-01-24 2007-08-02 Santarus, Inc. Formules pharmaceutiques utiles pour inhiber la secretion d’acide et procedes de fabrication et d’utilisation correspondants
JP2007224012A (ja) * 2006-01-30 2007-09-06 Fujifilm Corp 酵素架橋したタンパク質ナノ粒子
US20070184111A1 (en) * 2006-02-03 2007-08-09 Pharmavite Llc Hybrid tablet
US20070190131A1 (en) * 2006-02-10 2007-08-16 Perry Ronald L Press-fit rapid release medicament and method and apparatus of manufacturing
US20070224258A1 (en) * 2006-03-22 2007-09-27 Bunick Frank J Dosage forms having a randomized coating
JP2009531460A (ja) * 2006-03-28 2009-09-03 マクニール−ピーピーシー・インコーポレイテッド 不均一な投薬形態コーティング
CN104825397A (zh) 2006-04-03 2015-08-12 伊萨·奥迪迪 含有机溶胶涂层的受控释放递送物件
CA2648278C (fr) * 2006-04-03 2019-05-28 Isa Odidi Composition d'administration de medicament
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20070293587A1 (en) * 2006-05-23 2007-12-20 Haley Jeffrey T Combating sinus, throat, and blood infections with xylitol delivered in the mouth
WO2007139661A1 (fr) * 2006-05-23 2007-12-06 Haley Jeffrey T Trochisques à base de xilitol et leurs procédés d'utilisation
SG10201503411QA (en) 2006-08-03 2015-06-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8399230B2 (en) * 2006-10-12 2013-03-19 Kemin Industries, Inc. Heat-stable enzyme compositions
EP1916006A1 (fr) * 2006-10-19 2008-04-30 Albert Schömig Implant revêtu de cire ou de résine
KR20090094076A (ko) 2006-10-20 2009-09-03 맥네일-피피씨, 인코포레이티드 아세트아미노펜／이부프로펜 병용물
AU2007308986A1 (en) * 2006-10-25 2008-05-02 Mcneil-Ppc, Inc. Ibuprofen composition
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US7767248B2 (en) 2007-02-02 2010-08-03 Overly Iii Harry J Soft chew confectionary with high fiber and sugar content and method for making same
JP5224790B2 (ja) * 2007-03-02 2013-07-03 株式会社明治 固形食品およびその製造方法
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20080292692A1 (en) * 2007-05-21 2008-11-27 Shira Pilch Impermeable Capsules
US20080300322A1 (en) * 2007-06-01 2008-12-04 Atlantic Pharmaceuticals, Inc. Delivery vehicles containing rosin resins
WO2008148798A2 (fr) 2007-06-04 2008-12-11 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
RU2462226C2 (ru) * 2007-06-11 2012-09-27 Дзе Проктер Энд Гэмбл Компани Оказывающий благоприятное воздействие агент, содержащий доставляющие частицы
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
CN101801350A (zh) 2007-08-13 2010-08-11 阿巴斯迪特宁医药有限公司 抗滥用药物、使用方法和制备方法
JP2010539184A (ja) * 2007-09-12 2010-12-16 エラン・ファルマ・インターナショナル・リミテッド 投薬レジメン
US8741329B2 (en) * 2007-09-21 2014-06-03 Merck Sharp & Dohme B.V. Drug delivery system
FR2921835B1 (fr) * 2007-10-05 2012-05-04 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage comprenant du polydextrose, procede pour sa preparation et utilisation pour enrober les formes solides ingerables
MY147827A (en) † 2007-10-19 2013-01-31 Otsuka Pharma Co Ltd Pharmaceutical solid preparation
US8771643B2 (en) 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
CA2713128C (fr) 2008-01-25 2016-04-05 Gruenenthal Gmbh Forme posologique pharmaceutique
WO2009154810A2 (fr) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Systèmes d'administration de multiples principes actifs
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CA2720108C (fr) 2008-03-11 2016-06-07 Depomed, Inc. Formes medicamenteuses a liberation etendue de retention gastrique comprenant des combinaisons d'un analgesique non opioide et d'un analgesique opioide
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
EP2273983B1 (fr) 2008-05-09 2016-07-20 Grünenthal GmbH Procédé de préparation d'une formulation de poudre intermédiaire et d'une forme galénique solide finale en utilisant une étape de congélation par pulvérisation
EP2297793A4 (fr) * 2008-05-14 2014-08-06 Intercontinental Great Brands Llc Confiserie à texture modifiée de manière enzymatique
WO2009146537A1 (fr) * 2008-06-02 2009-12-10 Pharmascience Inc. Système multicouche d'apport de médicament à libération progressive
KR200452140Y1 (ko) * 2008-06-20 2011-02-08 주식회사 부성시스템 비닐하우스의 부직포개폐기용 제어장치
WO2010007623A1 (fr) 2008-07-14 2010-01-21 Polypid Ltd. Composition de véhicule de médicament à libération prolongée
KR200450450Y1 (ko) * 2008-07-16 2010-10-04 이봉석 포지션 리미트 스위치 케이스
US20110136921A1 (en) * 2008-08-07 2011-06-09 Nilesh Tanhaji Dumbre Sustained release composition
US8038424B2 (en) * 2008-09-22 2011-10-18 Xerox Corporation System and method for manufacturing sold ink sticks with an injection molding process
FR2936952A1 (fr) * 2008-10-09 2010-04-16 Monique Bellec Administration par voie orale de medicaments et complements nutritionnels
IT1394597B1 (it) * 2008-11-05 2012-07-05 Politi Granulazione a secco in flusso di gas.
WO2010067478A1 (fr) * 2008-12-12 2010-06-17 株式会社ミツヤコーポレーション Aliment et son procédé de traitement
WO2010084188A1 (fr) * 2009-01-26 2010-07-29 Nitec Pharma Ag Traitement de l'asthme par glucocorticoïde à libération retardée
WO2010088911A1 (fr) 2009-02-06 2010-08-12 Egalet A/S Compositions pharmaceutiques résistant à une maltraitance
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
LT2395840T (lt) * 2009-02-13 2020-07-10 Romark Laboratories, L.C. Nitazoksanido kontroliuojamo atpalaidavimo farmacinės kompozicijos
MY161146A (en) 2009-04-28 2017-04-14 Proteus Digital Health Inc Highly-reliable ingestible event markers and methods for using the same
MX2011011918A (es) * 2009-05-12 2012-01-27 Bpsi Holdings Llc Recubrimientos de pelicula que contienen reductores de adhesividad con particula fina y sustratos recubiertos con dichos recubrimientos.
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
WO2010149169A2 (fr) 2009-06-24 2010-12-29 Egalet A/S Formulations à libération contrôlée
JP5738856B2 (ja) 2009-07-14 2015-06-24 ポリピッド リミテッド 徐放性薬物担体組成物
TW201105316A (en) 2009-07-22 2011-02-16 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
EP2662076A1 (fr) 2009-07-22 2013-11-13 Grünenthal GmbH Forme galénique inviolable stabilisée à l'oxydation
MX2012000197A (es) * 2009-07-24 2012-02-28 Nihon Kraft Foods Ltd Dulce de regiones multiples y metodo de elaboracion para ello.
CA2769652A1 (fr) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Inhibiteurs macrocycliques de la serine protease macrocyclique utiles contre les infections virales, en particulier le virus de l?hepatite c
US20120141584A1 (en) * 2009-08-26 2012-06-07 Aptapharma, Inc. Multilayer Minitablets
RU2012112552A (ru) * 2009-08-31 2013-10-10 Дипомед, Инк. Удерживаемые в желудке фармацевтические композиции для немедленного и продленного высвобождения ацетаминофена
BR112012004679A2 (pt) 2009-09-01 2020-08-11 Rhodia Operations composições poliméricas
EP2316432A1 (fr) * 2009-10-30 2011-05-04 ratiopharm GmbH Composition contenant de la fésotérodine et des fibres alimentaires
WO2011056764A1 (fr) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Imidazo[2,1-b][1,3]benzothiazoles enrichis en isotopes ou fluores
UA109424C2 (uk) * 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
WO2011067667A2 (fr) 2009-12-02 2011-06-09 Eurand Pharmaceuticals Limited Microcapsules de fexofénadine et compositions les contenant
EP2509587A2 (fr) * 2009-12-07 2012-10-17 McNeil-PPC, Inc. Revêtement par immersion partielle de formes pharmaceutiques pour libération modifiée
AU2010330862B2 (en) 2009-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
WO2011078993A1 (fr) * 2009-12-21 2011-06-30 Aptapharma, Inc. Comprimés multicouches à enrobage fonctionnel
AU2011208374B2 (en) 2010-01-19 2016-09-08 Polypid Ltd. Sustained-release nucleic acid matrix compositions
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
CN102821757B (zh) 2010-02-03 2016-01-20 格吕伦塔尔有限公司 通过挤出机制备粉末状药物组合物
US9205577B2 (en) * 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
WO2011112689A2 (fr) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Sels d'indazolylpyrrolotriazine
US20130059062A1 (en) * 2010-03-11 2013-03-07 Ramakant Kashinath Gundu Device For The Manufacture Of A Dosage Form With A Hole And Method Of Manufacture
US8486013B2 (en) * 2010-03-18 2013-07-16 Biotronik Ag Balloon catheter having coating
US9743688B2 (en) 2010-03-26 2017-08-29 Philip Morris Usa Inc. Emulsion/colloid mediated flavor encapsulation and delivery with tobacco-derived lipids
KR20170121299A (ko) 2010-04-07 2017-11-01 프로테우스 디지털 헬스, 인코포레이티드 소형의 섭취가능한 장치
US11202853B2 (en) * 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
EP3848040A1 (fr) 2010-05-12 2021-07-14 Spectrum Pharmaceuticals, Inc. Dioxycarbonate de lanthane, et leur utilisation
US20110280936A1 (en) * 2010-05-17 2011-11-17 Aptapharma, Inc. Self Breaking Tablets
WO2011161666A2 (fr) * 2010-06-21 2011-12-29 White Innovation Ltd. Inclusion de liquides dans des capsules
JP5872558B2 (ja) 2010-09-01 2016-03-01 アムビト ビオスシエンセス コルポラチオン ピラゾリルアミノキナゾリンの臭化水素酸塩
JP5933554B2 (ja) 2010-09-01 2016-06-15 アムビト ビオスシエンセス コルポラチオン 光学活性のあるピラゾリルアミノキナゾリン及びその医薬組成物及び使用方法
TWI516286B (zh) 2010-09-02 2016-01-11 歌林達股份有限公司 含陰離子聚合物之抗破碎劑型
CN103269688A (zh) 2010-09-02 2013-08-28 格吕伦塔尔有限公司 包含无机盐的抗破碎剂型
WO2012071280A2 (fr) 2010-11-22 2012-05-31 Proteus Biomedical, Inc. Dispositif ingérable avec produit pharmaceutique
US20140079686A1 (en) 2010-12-06 2014-03-20 Shikha P. Barman Methods For Treating Baldness And Promoting Hair Growth
US10821085B2 (en) * 2010-12-07 2020-11-03 Kimberly-Clark Worldwide, Inc. Wipe coated with a botanical composition having antimicrobial properties
AU2011342893A1 (en) 2010-12-13 2013-05-02 Purdue Pharma L.P. Controlled release dosage forms
WO2012080050A1 (fr) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Formes solides d'un composé de phénoxybenzènesulfonyle
WO2012106299A1 (fr) 2011-01-31 2012-08-09 Celgene Corporation Compositions pharmaceutiques d'analogues de cytidine et leurs méthodes d'utilisation
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2717813B1 (fr) * 2011-06-06 2020-05-20 Auritec Pharmaceuticals Dispositif d'administration de médicament employant une fenêtre de libération par inhibition par capillarité
USD723766S1 (en) 2011-06-30 2015-03-10 Intercontinental Great Brands Llc Confectionary article
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
WO2015112603A1 (fr) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Produit ingérable pouvant être mâché et système de communication associé
EA201400172A1 (ru) 2011-07-29 2014-06-30 Грюненталь Гмбх Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
NO2736497T3 (fr) 2011-07-29 2018-01-20
US9084439B2 (en) * 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
CA2851544C (fr) 2011-10-14 2016-08-09 Hill's Pet Nutrition, Inc. Procede de preparation d'une composition alimentaire
KR101384055B1 (ko) * 2012-02-02 2014-04-14 한국원자력연구원 버스트형 지연 방출 제어 조성물 및 이의 제조방법
CA2864949A1 (fr) 2012-02-28 2013-09-06 Grunenthal Gmbh Forme pharmaceutique inviolable comprenant un compose pharmacologiquement actif et un polymere anionique
US8916555B2 (en) 2012-03-16 2014-12-23 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
US20130261372A1 (en) * 2012-03-30 2013-10-03 Elwha LLC, a limited liability company of the State of Delaware Device, System, and Method for Delivery of Sugar Glass Stabilized Compositions
WO2013156453A1 (fr) 2012-04-18 2013-10-24 Grünenthal GmbH Forme pharmaceutique inviolable et résistante à la libération massive
WO2013165961A1 (fr) * 2012-04-30 2013-11-07 Bettinger, Christopher J. Batterie pouvant être ingérée activée par l'eau
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
TW201400146A (zh) 2012-06-05 2014-01-01 Takeda Pharmaceutical 有核錠
CN104684548A (zh) 2012-07-06 2015-06-03 埃格勒特有限责任公司 防止滥用的控释药物组合物
CN102824640A (zh) * 2012-08-06 2012-12-19 济南圣泉唐和唐生物科技有限公司 一种胶囊壳及其制备方法
US20140193543A1 (en) * 2013-01-09 2014-07-10 Alexander Vigneri Decorative hollow chocolate confection with improved writability
WO2014120669A1 (fr) 2013-01-29 2014-08-07 Proteus Digital Health, Inc. Films polymères hautement dilatables et compositions les contenant
DE102013004263A1 (de) 2013-03-13 2014-09-18 Martin Lipsdorf Schnell lösliche orale Darreichungsform und Methode zur Herstellung derselben
CN105163722A (zh) 2013-03-15 2015-12-16 英秋博实验室有限公司 多阶段生物可降解药物递送平台
US20140275038A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
WO2014144738A1 (fr) 2013-03-15 2014-09-18 Proteus Digital Health, Inc. Appareil, système et procédé de détection de métal
US9470489B2 (en) * 2013-05-14 2016-10-18 Kerry Thaddeus Bowden Airsoft marking round
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
WO2014191396A1 (fr) 2013-05-29 2014-12-04 Grünenthal GmbH Forme dosifiée inviolable à profil de libération bimodale
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (fr) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibiteurs du virus de l'hépatite c
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
BR112016010482B1 (pt) 2013-11-26 2022-11-16 Grünenthal GmbH Preparação de uma composição farmacêutica em pó por meio de criomoagem
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
EP3079659B1 (fr) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Système d'administration de médicaments pour la fourniture d'antiviraux
JP2017507165A (ja) * 2013-12-16 2017-03-16 マサチューセッツ インスティテュート オブ テクノロジー マイクロモールド成形された、または３次元印刷されたパルス放出ワクチン製剤
US9375033B2 (en) 2014-02-14 2016-06-28 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
TWI807150B (zh) 2014-03-20 2023-07-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
CA2943231C (fr) 2014-03-20 2023-10-24 Capella Therapeutics, Inc. Derives de benzimidazole en tant qu'inhibiteurs de la tyrosine kinase erbb pour le traitement du cancer
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CN107250116B (zh) 2014-12-23 2020-10-27 艾士盟医疗公司 3,5-二氨基吡唑激酶抑制剂
DE202016008309U1 (de) * 2015-01-22 2017-07-14 Pfeifer & Langen GmbH & Co. KG Cellobiosehaltige Zuckermasse
US10174275B2 (en) * 2015-01-30 2019-01-08 Follmann Gmbh & Co. Kg Thermally opening stable core/shell microcapsules
USD765828S1 (en) 2015-02-19 2016-09-06 Crossford International, Llc Chemical tablet
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN108712900A (zh) 2015-12-19 2018-10-26 第时间美国泛型药物有限公司 软咀嚼片剂药物制剂
US20190022013A1 (en) 2015-12-19 2019-01-24 First Time Us Generics Llc Soft-chew tablet pharmaceutical formulations
JP2017158534A (ja) * 2016-03-07 2017-09-14 焼津水産化学工業株式会社 チップ状食品の製造方法及びチップ状食品
JP6552148B1 (ja) 2016-07-22 2019-07-31 プロテウス デジタル ヘルス， インコーポレイテッド 摂取可能なイベント・マーカの電磁気的感知および検出
AU2017322186A1 (en) * 2016-09-09 2019-05-02 Merck Patent Gmbh Process for the manufacture of a solid pharmaceutical adminstration form
WO2018058009A1 (fr) 2016-09-26 2018-03-29 The Procter & Gamble Company Forme galénique à libération prolongée
WO2018081337A1 (fr) 2016-10-26 2018-05-03 Proteus Digital Health, Inc. Procédés de préparation de capsules avec des marqueurs d'événement ingérables
CN106945323B (zh) * 2017-03-14 2018-11-02 常熟市双月机械有限公司 一种高效率的金属粉末液压机
EP3606751A1 (fr) * 2017-04-07 2020-02-12 The Procter and Gamble Company Films hydrosolubles
DE102017107845A1 (de) * 2017-04-11 2018-10-11 Gelita Ag Gelatineprodukt mit einer Kernkomponente und Verfahren zu dessen Herstellung
US10450119B2 (en) 2017-06-22 2019-10-22 The Procter & Gamble Company Films including a water-soluble layer and a vapor-deposited inorganic coating
ES2963042T3 (es) 2017-06-22 2024-03-25 Procter & Gamble Películas que incluyen una capa soluble en agua y un recubrimiento orgánico depositado por vapor
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11000471B2 (en) * 2018-03-05 2021-05-11 Kashiv Specialty Pharmaceuticals, Llc Programmable pharmaceutical compositions for chrono drug release
EP3587467A1 (fr) * 2018-06-25 2020-01-01 Rudolf GmbH Particule c ur-écorce fonctionnelle à parois multiples
WO2020006362A1 (fr) * 2018-06-28 2020-01-02 Mars, Incorporated Formulations d'encre comestible améliorées comprenant du carbonate de calcium
KR102151342B1 (ko) * 2019-03-18 2020-09-02 박문수 구강용 캡슐 및 이의 제조방법
CN110006918B (zh) * 2019-04-17 2021-04-30 湖北三环锻造有限公司 一种用于渗透探伤工艺的渗透探伤剂
EP4009815A4 (fr) * 2019-09-12 2023-09-06 Nulixir Inc. Particules noyau-enveloppe à libération contrôlée et suspensions les comprenant
CA3124579A1 (fr) 2020-07-15 2022-01-15 Schabar Research Associates Llc Compositions de doses orales unitaires composees de naproxene sodique et de famotidine pour le traitement des douleurs aigues et la reduction de la gravite des aigreurs et/ou du risque d'aigreurs
BR112023000598A2 (pt) 2020-07-15 2023-01-31 Schabar Res Associates Llc Composições de dose oral unitária composta de ibuprofeno e famotidina para o tratamento da dor aguda e redução da gravidade e/ou risco de azia

Citations (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US582438A (en) * 1897-05-11 John scheidler
US3085942A (en) * 1960-12-28 1963-04-16 Hoffmann La Roche Antitussive compositions and preparation
US3185626A (en) * 1963-03-06 1965-05-25 Sterling Drug Inc Tablet coating method
US3670065A (en) * 1968-06-19 1972-06-13 Karl Gunnar Eriksson Process for producing dosage units of a type resembling tablets
US3726622A (en) * 1971-08-20 1973-04-10 Wolverine Pentronix Compacting apparatus
US3804570A (en) * 1971-11-19 1974-04-16 Werner & Pfleiderer Block press
US4076819A (en) * 1975-05-30 1978-02-28 Parcor Thieno-pyridine derivatives and therapeutic composition containing same
US4139589A (en) * 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US4139627A (en) * 1977-10-06 1979-02-13 Beecham Inc. Anesthetic lozenges
US4198390A (en) * 1979-01-31 1980-04-15 Rider Joseph A Simethicone antacid tablet
US4218433A (en) * 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4273793A (en) * 1979-10-26 1981-06-16 General Foods Corporation Apparatus and process for the preparation of gasified confectionaries by pressurized injection molding
US4279926A (en) * 1974-03-07 1981-07-21 Spa-Societa Prodotti Antibiotici S.P.A. Method of relieving pain and treating inflammatory conditions in warm-blooded animals
US4322449A (en) * 1978-11-15 1982-03-30 Boehringer Ingelheim Gmbh Pharmaceuticals having dotted active ingredients and a method and apparatus for the preparation thereof
US4392493A (en) * 1979-09-06 1983-07-12 Dawsonville Corp., N.V. Tattooing apparatus
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4517205A (en) * 1983-01-03 1985-05-14 Nabisco Brands, Inc. Co-deposited two-component hard candy
US4533345A (en) * 1983-06-14 1985-08-06 Fertility & Genetics Associates Uterine catheter
US4564525A (en) * 1984-03-30 1986-01-14 Mitchell Cheryl R Confection products
US4569650A (en) * 1984-02-07 1986-02-11 Kilian & Co., Gmbh Tablet press
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4663147A (en) * 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
US4683256A (en) * 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
US4813818A (en) * 1987-08-25 1989-03-21 Michael Sanzone Apparatus and method for feeding powdered materials
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
US4828841A (en) * 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
US4853230A (en) * 1986-04-30 1989-08-01 Aktiebolaget Hassle Pharmaceutical formulations of acid labile substances for oral use
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US4984240A (en) * 1988-12-22 1991-01-08 Codex Corporation Distributed switching architecture for communication module redundancy
US4983394A (en) * 1990-05-03 1991-01-08 Warner-Lambert Company Flavor enhancing and medicinal taste masking agent
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5004614A (en) * 1988-08-26 1991-04-02 Forum Chemicals Ltd. Controlled release device with an impermeable coating having an orifice for release of drug
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5133892A (en) * 1990-10-17 1992-07-28 Lever Brothers Company, Division Of Conopco, Inc. Machine dishwashing detergent tablets
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5393533A (en) * 1988-09-09 1995-02-28 The Ronald T. Dodge Company Pharmaceuticals microencapsulated by vapor deposited polymers and method
US5405642A (en) * 1991-02-27 1995-04-11 Janssen Pharmaceutica N.V. Method of highlighting intagliations in tablets
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5424075A (en) * 1991-03-27 1995-06-13 Miles Inc. Delivery system for enhanced onset and increased potency
US5427614A (en) * 1992-02-14 1995-06-27 Warner-Lambert Company Starch based formulations
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
US5510385A (en) * 1993-06-21 1996-04-23 Zambon Group S.P.A. Pharmaceutical compositions containing the salts of S(+)-2-(4-isobutylphenyl)propionic acid with basic aminoacids
US5538125A (en) * 1990-11-05 1996-07-23 Mcneil-Ppc, Inc. Indexing and feeding systems for apparatus for gelatin coating tablets
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5610214A (en) * 1988-12-29 1997-03-11 Deknatel Technology Corporation, Inc. Method for increasing the rate of absorption of polycaprolactone
US5627971A (en) * 1995-06-01 1997-05-06 Northern Telecom Limited Machine method for determining the eligibility of links in a network
US5626875A (en) * 1995-02-01 1997-05-06 Esteve Quimica, S.A. Stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
US5630871A (en) * 1991-01-17 1997-05-20 Berwind Pharmaceutical Services, Inc. Film coatings and film coating compositions based on cellulosic polymers and lactose
US5641536A (en) * 1993-08-30 1997-06-24 Warner-Lambert Company Tablet coating method
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5658589A (en) * 1989-04-28 1997-08-19 Mcneil-Ppc, Inc. Subcoated simulated capsule-like medicament
US5738874A (en) * 1992-09-24 1998-04-14 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation
US5861173A (en) * 1995-11-28 1999-01-19 Bayer Aktiengesellschaft Long-lasting release nifedipine preparation
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US5912013A (en) * 1991-07-23 1999-06-15 Shire Laboratories, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US6013281A (en) * 1995-02-09 2000-01-11 Astra Aktiebolag Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
US6077541A (en) * 1997-11-14 2000-06-20 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6090401A (en) * 1999-03-31 2000-07-18 Mcneil-Ppc, Inc. Stable foam composition
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6183776B1 (en) * 1996-01-08 2001-02-06 Astra Aktiebolag Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
US6207198B1 (en) * 1995-09-21 2001-03-27 Schwarz Pharma Ag Composition containing an acid-labile omeprazole and process for its preparation
US6217902B1 (en) * 1995-06-09 2001-04-17 R. P. Scheier Company Soft gelatin capsules containing particulate material
US6224910B1 (en) * 1998-05-22 2001-05-01 Bristol-Myers Squibb Company Method for the preparation of an enteric coated high drug load pharmaceutical composition
US20010001280A1 (en) * 1998-09-09 2001-05-17 Liang-Chang Dong Dosage form comprising liquid formulation
US6248361B1 (en) * 1999-02-26 2001-06-19 Integ, Ltd. Water-soluble folic acid compositions
US6264985B1 (en) * 1994-09-06 2001-07-24 Lts Lohmann Therapie-Systeme Gmbh Laminated tablet with pointed core
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US20020051807A1 (en) * 2000-01-13 2002-05-02 Joaquina Faour Osmotic device containing alprazolam and an antipsychotic agent
US6394094B1 (en) * 1998-05-01 2002-05-28 Enhance Pharmaceuticals, Inc. Method for injection molding manufacture of controlled release devices
US20020082299A1 (en) * 1997-06-25 2002-06-27 Hans Meyer Method for reducing body weight
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
US20030060393A1 (en) * 1999-12-29 2003-03-27 Reckitt Benckiser N.V. Composition for use in a dishwasher
US20030066068A1 (en) * 2001-09-28 2003-04-03 Koninklijke Philips Electronics N.V. Individual recommender database using profiles of others
US20030068367A1 (en) * 2001-09-28 2003-04-10 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20030068373A1 (en) * 2001-09-28 2003-04-10 Joseph Luber Immediate release tablet
US20030070903A1 (en) * 2001-09-28 2003-04-17 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US6555139B2 (en) * 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US20030086973A1 (en) * 2001-09-28 2003-05-08 Sowden Harry S Systems, methods and apparatuses for manufacturing dosage forms
US6569457B2 (en) * 1998-07-17 2003-05-27 Bristol-Myers Squibb Company Enteric coated pharmaceutical tablet and method of manufacturing
US20030124183A1 (en) * 2001-09-28 2003-07-03 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US6727200B2 (en) * 2000-08-31 2004-04-27 Mra Laboratories, Inc. High dielectric constant very low fired X7R ceramic capacitor, and powder for making
US6726927B2 (en) * 1997-05-09 2004-04-27 Sage Pharmaceuticals, Inc. Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole
US6730646B1 (en) * 1998-07-29 2004-05-04 Reckitt Benckiser N.V. Composition for use in a dishwasher
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms

Family Cites Families (344)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US231117A (en) * 1880-08-10 Folding boat
US3371136A (en) 1968-02-27 United States Borax Chem Detergent tablet forming machine
US231062A (en) * 1880-08-10 Felt hat
US231024A (en) * 1880-08-10 Machine for lining sheets of straw-board
US542614A (en) * 1895-07-09 Office
US231129A (en) * 1880-08-10 wiesebrook
US231163A (en) * 1880-08-17 hamlin
US599865A (en) * 1898-03-01 Emanuel l
US966450A (en) * 1909-06-18 1910-08-09 John W S Jones Couch or bed.
US966509A (en) * 1909-06-25 1910-08-09 Charles A Wulf Flushing-valve.
US967414A (en) * 1910-02-11 1910-08-16 William W Hallam Railway-rail.
US966939A (en) * 1910-05-02 1910-08-09 James V Mitchell Sash-lock.
US996497A (en) * 1911-03-30 1911-06-27 Kokomo Sanitary Mfg Co Tank-cover fastener.
US1036647A (en) 1911-06-19 1912-08-27 St Louis Briquette Machine Company Briquet-machine.
US1437816A (en) 1922-07-26 1922-12-05 Howard S Paine Process for preparing fondant or chocolate soft cream centers
US1505827A (en) * 1923-04-25 1924-08-19 Villasenor Eduardo Tablet-making machine
US1900012A (en) 1925-09-04 1933-03-07 Western Cartridge Co Process of and apparatus for making wads
US2307371A (en) * 1941-08-13 1943-01-05 Ray O Vac Co Molding process
US2415997A (en) 1946-01-12 1947-02-18 John W Eldred Article handling apparatus
US2823789A (en) 1952-05-06 1958-02-18 Gilman Engineering & Mfg Corp Parts feeder ribbon
US2996431A (en) * 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US2849965A (en) 1954-04-15 1958-09-02 John Holroyd & Company Ltd Machines for use in the production of coated tablets and the like
GB759081A (en) 1954-04-15 1956-10-10 John Holroyd And Company Ltd Improvements relating to machines for the production of coated tablets and the like
US2966431A (en) 1956-03-24 1960-12-27 Basf Ag Separation of filter material from carbon black
US2946298A (en) 1957-11-13 1960-07-26 Arthur Colton Company Compression coating tablet press
US2931276A (en) 1958-02-10 1960-04-05 Jagenberg Werke Ag Methods of and means for producing, processing, and for treating articles
GB866681A (en) 1958-05-22 1961-04-26 May & Baker Ltd N-substituted piperidines
GB888038A (en) 1959-12-16 1962-01-24 William Warren Triggs C B E Medicinal tablet
GB936386A (en) * 1959-01-16 1963-09-11 Wellcome Found Pellets for supplying biologically active substances to ruminants
US2963993A (en) 1959-01-20 1960-12-13 John Holroyd & Company Ltd Machines for making coated tablets by compression
US3096248A (en) 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3029752A (en) 1959-07-20 1962-04-17 Stokes F J Corp Tablet making machine
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
GB990784A (en) 1960-05-23 1965-05-05 Dunlop Rubber Co Improvements in or relating to balls
US3173876A (en) * 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
GB994742A (en) 1960-09-09 1965-06-10 Wellcome Found Pharmaceutical tablets containing anthelmintics, and the manufacture thereof
US3108046A (en) 1960-11-25 1963-10-22 Smith Kline French Lab Method of preparing high dosage sustained release tablet and product of this method
NL271831A (fr) * 1960-11-29
US3430535A (en) 1961-08-25 1969-03-04 Independent Lock Co Key cutter
BE636865A (fr) 1962-08-31
US3279995A (en) 1963-05-31 1966-10-18 Allen F Reid Shaped pellets
US3276586A (en) * 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3300063A (en) 1965-01-25 1967-01-24 Mayer & Co Inc O Vacuum gripping apparatus
FR1603314A (en) * 1965-02-23 1971-04-05 Pharmaceutical tablets - having a core and a matrix material
US3328840A (en) * 1965-04-23 1967-07-04 Pentronix Inc Powder compacting press
US3279360A (en) 1965-09-13 1966-10-18 Miehle Goss Dexter Inc Machine for printing on cylindrical articles
US3330400A (en) 1966-03-08 1967-07-11 Miehle Goss Dexter Inc Mechanism for transferring cylindrical articles
GB1212535A (en) 1966-10-12 1970-11-18 Shionogi & Co Method and apparatus for producing molded article
US3458968A (en) 1966-11-16 1969-08-05 Lester Gregory Jr Dispensing and feed mechanism
GB1144915A (en) * 1966-11-24 1969-03-12 Armour Pharma Improvements in or relating to pastille formulations
US3546142A (en) * 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3656518A (en) 1967-03-27 1972-04-18 Perry Ind Inc Method and apparatus for measuring and dispensing predetermined equal amounts of powdered material
US3563170A (en) 1968-04-16 1971-02-16 Reynolds Metals Co Machine for marking the exterior cylindrical surfaces of cans in a continous nonidexing manner
US3605479A (en) 1968-05-08 1971-09-20 Textron Inc Forming press
US3584114A (en) 1968-05-22 1971-06-08 Hoffmann La Roche Free-flowing powders
US3541006A (en) * 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
FR1581088A (fr) 1968-07-17 1969-09-12
US3567043A (en) 1968-08-05 1971-03-02 Sun Chemical Corp Transfer assembly for use with container printing machines
US3627583A (en) * 1969-04-29 1971-12-14 Sucrest Corp Direct compression vehicles
US3604417A (en) * 1970-03-31 1971-09-14 Wayne Henry Linkenheimer Osmotic fluid reservoir for osmotically activated long-term continuous injector device
US3640654A (en) * 1970-06-25 1972-02-08 Wolverine Pentronix Die and punch assembly for compacting powder and method of assembly
US3832252A (en) * 1970-09-29 1974-08-27 T Higuchi Method of making a drug-delivery device
NL175029C (nl) 1970-12-23 1984-09-17 Boehringer Sohn Ingelheim Depotdragee, die bekleed is met een onoplosbare en onverteerbare schaal, die op een of meer plaatsen een uitsparing vertoont.
US3811552A (en) 1971-01-11 1974-05-21 Lilly Co Eli Capsule inspection apparatus and method
US3760804A (en) * 1971-01-13 1973-09-25 Alza Corp Improved osmotic dispenser employing magnesium sulphate and magnesium chloride
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
GB1371244A (en) * 1971-12-09 1974-10-23 Howorth Air Conditioning Ltd Machines acting on continuously running textile yarns
BE794951A (fr) * 1972-02-03 1973-05-29 Parke Davis & Co Conditionnement soluble dans l'eau
US3975888A (en) 1972-04-26 1976-08-24 R. A. Jones & Company, Inc. Method and apparatus for forming, filling and sealing packages
US3851751A (en) 1972-04-26 1974-12-03 Jones & Co Inc R A Method and apparatus for forming, filling and sealing packages
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3912441A (en) 1972-12-13 1975-10-14 Yasuo Shimada Compressing roll in rotary power compression molding machine
US3851638A (en) 1973-02-02 1974-12-03 Kam Act Enterprises Inc Force multiplying type archery bow
DE2309202A1 (de) 1973-02-21 1974-08-29 Schering Ag Arzneiformen mit mikroverkapseltem arzneimittelwirkstoff
US3832525A (en) * 1973-03-26 1974-08-27 Raymond Lee Organization Inc Automatic heating device to prevent freezing of water supply lines
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3884143A (en) 1973-09-04 1975-05-20 Hartnett Co R W Conveyor link for tablet printing apparatus
DE2401419A1 (de) 1974-01-12 1975-07-17 Bosch Gmbh Robert Fahrzeug mit einem hydrostatischen und mechanischen antrieb
US3891375A (en) 1974-01-21 1975-06-24 Vector Corp Tablet press
US3988403A (en) * 1974-07-09 1976-10-26 Union Carbide Corporation Process for producing molded structural foam article having a surface that reproducibly and faithfully replicates the surface of the mold
US4230693A (en) * 1975-04-21 1980-10-28 Armour-Dial, Inc. Antacid tablets and processes for their preparation
US4097606A (en) * 1975-10-08 1978-06-27 Bristol-Myers Company APAP Tablet containing an alkali metal carboxymethylated starch and processes for manufacturing same
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
SE414386B (sv) 1976-03-10 1980-07-28 Aco Laekemedel Ab Sett att framstella och samtidigt forpacka farmaceutiska dosenheter
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
DE2752971C2 (de) 1977-11-28 1982-08-19 Lev Nikolaevič Moskva Koškin Spritzgießmaschine zum Herstellen von Spritzgußteilen aus thermoplastischen Werkstoffen
GB2030042A (en) * 1978-09-21 1980-04-02 Beecham Group Ltd Antacid fondant
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4304232A (en) * 1979-03-14 1981-12-08 Alza Corporation Unit system having multiplicity of means for dispensing useful agent
US4286497A (en) * 1979-06-18 1981-09-01 Shamah Alfred A Ratchet-securable toggle retainer
US4271142A (en) * 1979-06-18 1981-06-02 Life Savers, Inc. Portable liquid antacids
JPS5827162B2 (ja) 1979-08-24 1983-06-08 株式会社ヤクルト本社 定速搬送機構
DE2936040C2 (de) * 1979-09-06 1982-05-19 Meggle Milchindustrie Gmbh & Co Kg, 8094 Reitmehring Dragierverfahren und Mittel zur Durchführung des Verfahrens, bestehend im wesentlichen aus Saccharose, wenigstens einem weiteren Zucker und Wasser
US4271206A (en) * 1979-10-26 1981-06-02 General Foods Corporation Gasified candy having a predetermined shape
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4318746A (en) * 1980-01-08 1982-03-09 Ipco Corporation Highly stable gel, its use and manufacture
US4473526A (en) * 1980-01-23 1984-09-25 Eugen Buhler Method of manufacturing dry-pressed molded articles
US4292017A (en) 1980-07-09 1981-09-29 Doepel Wallace A Apparatus for compressing tablets
US4362757A (en) 1980-10-22 1982-12-07 Amstar Corporation Crystallized, readily water dispersible sugar product containing heat sensitive, acidic or high invert sugar substances
FR2492661A1 (fr) * 1980-10-28 1982-04-30 Laruelle Claude Nouvelle forme galenique d'administration du metoclopramide, son procede de preparation et medicament comprenant cette nouvelle forme
US4327076A (en) * 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4340054A (en) * 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US5002970A (en) * 1981-07-31 1991-03-26 Eby Iii George A Flavor masked ionizable zinc compositions for oral absorption
IE53102B1 (en) * 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
US4372942A (en) * 1981-08-13 1983-02-08 Beecham Inc. Candy base and liquid center hard candy made therefrom
DE3144678A1 (de) 1981-11-10 1983-05-19 Eugen Dipl.-Ing. 8871 Burtenbach Bühler Verfahren und einrichtung zur herstellung von formlingen aus einer rieselfaehigen masse
JPS58152813A (ja) 1982-03-08 1983-09-10 Sumitomo Chem Co Ltd 鮮明な刻印を有する錠剤およびその製法
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
US4882167A (en) 1983-05-31 1989-11-21 Jang Choong Gook Dry direct compression compositions for controlled release dosage forms
FR2548675B1 (fr) * 1983-07-06 1987-01-09 Seppic Sa Compositions filmogenes pour enrobage des formes solides de produits pharmaceutiques ou alimentaires et produits obtenus revetus desdites compositions
US4749575A (en) * 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4781714A (en) 1983-11-02 1988-11-01 Alza Corporation Dispenser for delivering thermo-responsive composition
AU591171B2 (en) 1983-11-02 1989-11-30 Alza Corporation Dispenser for delivering thermo-responsive composition
NL194820C (nl) 1983-11-02 2003-04-03 Alza Corp Preparaat voor de afgifte van een op warmte reagerende samenstelling.
US4518335A (en) * 1984-03-14 1985-05-21 Allied Corporation Dilatant mold and dilatant molding apparatus
JPS60217106A (ja) 1984-04-12 1985-10-30 高橋　信之 無機粉末凍結成形法
US4661521A (en) 1984-04-30 1987-04-28 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4528335A (en) * 1984-05-18 1985-07-09 Phillips Petroleum Company Polymer blends
US4666212A (en) * 1984-06-15 1987-05-19 Crucible S.A. Metal value recovery
US4610884A (en) 1984-06-29 1986-09-09 The Procter & Gamble Company Confectionery cremes
US4894234A (en) 1984-10-05 1990-01-16 Sharma Shri C Novel drug delivery system for antiarrhythmics
JPS61100519A (ja) * 1984-10-23 1986-05-19 Shin Etsu Chem Co Ltd 医薬用硬質カプセル
US4684534A (en) * 1985-02-19 1987-08-04 Dynagram Corporation Of America Quick-liquifying, chewable tablet
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4627971A (en) * 1985-04-22 1986-12-09 Alza Corporation Osmotic device with self-sealing passageway
CA1234717A (fr) * 1985-06-28 1988-04-05 Leslie F. Knebl Gomme a macher humide
GB8517073D0 (en) 1985-07-05 1985-08-14 Hepworth Iron Co Ltd Pipe pipe couplings &c
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
DK8603837A (fr) 1985-08-13 1987-02-14
US4665116A (en) 1985-08-28 1987-05-12 Turtle Wax, Inc. Clear cleaner/polish composition
US5188840A (en) 1985-09-26 1993-02-23 Chugai Seiyaku Kabushiki Kaisha Slow-release pharmaceutical agent
US4898733A (en) 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4853249A (en) 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
US5229164A (en) 1985-12-19 1993-07-20 Capsoid Pharma Gmbh Process for producing individually dosed administration forms
DE3601516A1 (de) * 1986-01-20 1987-07-23 Agie Ag Ind Elektronik Lichtschranke
JPS62230600A (ja) 1986-03-31 1987-10-09 東洋ゴム工業株式会社 伸縮可能なフオ−クを備えたフオ−クリフト
DE3610878A1 (de) 1986-04-01 1987-10-08 Boehringer Ingelheim Kg Formlinge aus pellets
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4960416A (en) * 1986-04-30 1990-10-02 Alza Corporation Dosage form with improved delivery capability
US5200196A (en) * 1986-05-09 1993-04-06 Alza Corporation Improvement in pulsed drug therapy
US4802924A (en) 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
IE58401B1 (en) * 1986-06-20 1993-09-08 Elan Corp Plc Controlled absorption pharmaceutical composition
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4762719A (en) * 1986-08-07 1988-08-09 Mark Forester Powder filled cough product
DE3629994A1 (de) 1986-09-03 1988-03-17 Weissenbacher Ernst Rainer Pro Vorrichtung zur medikamentenapplikation in koerperhoehlen bzw. auf koerperoberflaechen
CA1290526C (fr) * 1986-11-07 1991-10-15 Marianne Wieser Fonctionnement de matrice et poincon
DE3640574A1 (de) * 1986-11-27 1988-06-09 Katjes Fassin Gmbh & Co Kg Verfahren zur herstellung eines essbaren pralinenfoermigen produktes und vorrichtung fuer die durchfuehrung des verfahrens
US4828845A (en) * 1986-12-16 1989-05-09 Warner-Lambert Company Xylitol coated comestible and method of preparation
IT1201136B (it) 1987-01-13 1989-01-27 Resa Farma Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4808413A (en) 1987-04-28 1989-02-28 E. R. Squibb & Sons, Inc. Pharmaceutical compositions in the form of beadlets and method
US4792448A (en) * 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4978483A (en) 1987-09-28 1990-12-18 Redding Bruce K Apparatus and method for making microcapsules
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US4894236A (en) * 1988-01-12 1990-01-16 Choong-Gook Jang Direct compression tablet binders for acetaminophen
CA1330886C (fr) 1988-01-22 1994-07-26 Bend Research Inc. Systeme controle par la pression osmotique servant a la distribution de solutions diluees
CH676470A5 (fr) * 1988-02-03 1991-01-31 Nestle Sa
US4929446A (en) * 1988-04-19 1990-05-29 American Cyanamid Company Unit dosage form
US5279660A (en) * 1988-05-24 1994-01-18 Berol Nobel Stenungsund Ab Use of viscosity-adjusting agent to counteract viscosity decrease upon temperature increase of a water-based system
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
US5194464A (en) * 1988-09-27 1993-03-16 Takeda Chemical Industries, Ltd. Enteric film and preparatoin thereof
JPH0816051B2 (ja) 1988-12-07 1996-02-21 エスエス製薬株式会社 徐放性坐剤
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5006297A (en) * 1989-02-22 1991-04-09 Acushnet Company Method of molding polyurethane covered golf balls
US4956182A (en) 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US4931286A (en) * 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US4960169A (en) * 1989-06-20 1990-10-02 Modien Manufacturing Co. Baffle for tubular heat exchanger header
US4992277A (en) * 1989-08-25 1991-02-12 Schering Corporation Immediate release diltiazem formulation
EP0419410A3 (en) 1989-09-19 1991-08-14 Ciba-Geigy Ag Alkanophenones
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
DK469989D0 (da) 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
JPH03139496A (ja) * 1989-10-25 1991-06-13 Sanshin Ind Co Ltd 船舶推進機
US5169645A (en) 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
FR2655266B1 (fr) * 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
US5223266A (en) * 1990-01-24 1993-06-29 Alza Corporation Long-term delivery device with early startup
US5100676A (en) * 1990-02-02 1992-03-31 Biosurface Technology, Inc. Cool storage of cultured epithelial sheets
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
US4980169A (en) 1990-05-03 1990-12-25 Warner-Lambert Company Flavor enhancing and increasing efficacy of cough drops
US5089270A (en) 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5075114A (en) 1990-05-23 1991-12-24 Mcneil-Ppc, Inc. Taste masking and sustained release coatings for pharmaceuticals
US5464631A (en) 1990-06-27 1995-11-07 Warner-Lambert Company Encapsulated dosage forms
US5436026A (en) * 1990-11-05 1995-07-25 Mcneil-Ppc, Inc. Discharge and transfer system for apparatus for gelatin coating tablets
US5228916A (en) 1990-11-05 1993-07-20 Mcneil-Ppc, Inc. Apparatus for creating a gelatin coating
US5503673A (en) 1990-11-05 1996-04-02 Mcneil-Ppc, Inc Apparatus for dip coating product
US5683719A (en) * 1990-11-22 1997-11-04 British Technology Group Limited Controlled release compositions
US5098715A (en) * 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
CA2068402C (fr) * 1991-06-14 1998-09-22 Michael R. Hoy Enrobage pour masquer le gout pouvant etre utilise dans des comprimes pharmaceutiques croquables
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5314696A (en) * 1991-06-27 1994-05-24 Paulos Manley A Methods for making and administering a blinded oral dosage form and blinded oral dosage form therefor
US5190927A (en) * 1991-07-09 1993-03-02 Merck & Co., Inc. High-glyceryl, low-acetyl gellan gum for non-brittle gels
US5200191A (en) 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
US5200195A (en) 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
DK171536B1 (da) 1991-12-06 1996-12-23 Rasmussen Kann Ind As Vindue med ramme af ekstruderede profilemner
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
GB2284760B (en) * 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5209746A (en) * 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
GR1002332B (el) 1992-05-21 1996-05-16 Mcneil-Ppc Inc. Νεες φαρμακευτικες συνθεσεις που περιεχουν σιμεθεικονη.
EP0572731A1 (fr) 1992-06-01 1993-12-08 The Procter & Gamble Company Composition à mâcher contenant un agent de décongestion
US5317849A (en) * 1992-08-07 1994-06-07 Sauter Manufacturing Corporation Encapsulation equipment and method
JPH07507564A (ja) 1992-09-30 1995-08-24 ファイザー・インク． コア及び厚さが一定でないコーティングを含有する物品
WO1994012157A1 (fr) * 1992-11-30 1994-06-09 Kv Pharmaceutical Company Substances pharmaceutiques au gout camoufle
US5375963A (en) 1993-01-19 1994-12-27 Wohlwend; Clayton E. Multipurpose lifting apparatus
TW272942B (fr) 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
US5391378A (en) * 1993-02-22 1995-02-21 Elizabeth-Hata International, Inc. Two-part medicinal tablet and method of manufacture
JP2524955B2 (ja) 1993-04-22 1996-08-14 トーワ株式会社 電子部品の樹脂封止成形方法及び装置
EP0621032B1 (fr) * 1993-04-23 2000-08-09 Novartis AG Dispositif d'administration de médicaments à libération contrôlée
IL119660A (en) 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
US5415868A (en) * 1993-06-09 1995-05-16 L. Perrigo Company Caplets with gelatin cover and process for making same
JP3054989B2 (ja) * 1993-06-19 2000-06-19 八幡 貞男 断熱発現容器
ZA944949B (en) * 1993-07-12 1995-04-05 Smithkline Beecham Corp Matrix-entrapped beadlet preparation
US5518551A (en) * 1993-09-10 1996-05-21 Fuisz Technologies Ltd. Spheroidal crystal sugar and method of making
US5397574A (en) * 1993-10-04 1995-03-14 Andrx Pharmaceuticals, Inc. Controlled release potassium dosage form
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
DE4341442C2 (de) * 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Vorrichtung zur kontrollierten Freisetzung von Wirkstoffen sowie ihre Verwendung
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US6060639A (en) * 1994-03-04 2000-05-09 Mentor Corporation Testicular prosthesis and method of manufacturing and filling
US5453920A (en) * 1994-03-08 1995-09-26 Eubanks; William W. Trouble light having a shroud with see-through opening
US5559110A (en) 1994-03-09 1996-09-24 The Dupont Merck Pharmaceutical Company Pharmaceutical formulations of cyclic urea type compounds
JPH07281423A (ja) * 1994-04-07 1995-10-27 Konica Corp 印刷版の製版方法
US5464633A (en) 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
US6020002A (en) * 1994-06-14 2000-02-01 Fuisz Technologies Ltd. Delivery of controlled-release system(s)
EE03305B1 (et) 1994-07-08 2000-12-15 Astra Aktiebolag Paljuosaline tableteeritud annusvorm I
US5788979A (en) * 1994-07-22 1998-08-04 Inflow Dynamics Inc. Biodegradable coating with inhibitory properties for application to biocompatible materials
IT1274034B (it) * 1994-07-26 1997-07-14 Applied Pharma Res Composizioni farmaceutiche a base di gomma da masticare e procedimento per la loro preparazione
US5849327A (en) 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
EP0773866B1 (fr) * 1994-08-03 1998-04-08 Gunter Meinhardt Voss Procede de fabrication de comprimes enrobes
DE9414065U1 (de) * 1994-08-31 1994-11-03 Röhm GmbH & Co. KG, 64293 Darmstadt Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen
US5733575A (en) * 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
GB9421837D0 (en) * 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5756123A (en) * 1994-12-01 1998-05-26 Japan Elanco Co., Ltd. Capsule shell
US5626896A (en) * 1994-12-09 1997-05-06 A.E. Staley Manufacturing Co. Method for making liquid-centered jelly candies
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
DE4446468A1 (de) * 1994-12-23 1996-06-27 Basf Ag Verfahren zur Herstellung von umhüllten Tabletten
US6471994B1 (en) * 1995-01-09 2002-10-29 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
ES2124956T3 (es) * 1995-02-07 1999-02-16 Hermann Kronseder Estrella de transporte para recipientes.
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5827874A (en) 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
CZ352097A3 (cs) 1995-05-09 1998-04-15 Colorcon Limited Způsob a materiál pro elektrostatické potahování jádra farmaceutických tablet
ES2129902T3 (es) * 1995-05-13 1999-06-16 Hermann Kronseder Rueda transportadora en estrella para recipientes.
US5578336A (en) 1995-06-07 1996-11-26 Monte; Woodrow C. Confection carrier for vitamins, enzymes, phytochemicals and ailmentary vegetable compositions and method of making
US5614207A (en) * 1995-06-30 1997-03-25 Mcneil-Ppc, Inc. Dry mouth lozenge
GB9517031D0 (en) 1995-08-19 1995-10-25 Procter & Gamble Confection compositions
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE19539361A1 (de) 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von mehrschichtigen, festen Arzneiformen zur oralen oder rektalen Verabreichung
IT1279673B1 (it) * 1995-11-07 1997-12-16 Acma Spa Apparecchiatura e metodo per la formazione di gruppi ordinati di prodotti da alimentare a passo.
US5733578A (en) * 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
US5807579A (en) * 1995-11-16 1998-09-15 F.H. Faulding & Co. Limited Pseudoephedrine combination pharmaceutical compositions
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US5879728A (en) * 1996-01-29 1999-03-09 Warner-Lambert Company Chewable confectionary composition and method of preparing same
IT1282576B1 (it) 1996-02-06 1998-03-31 Jagotec Ag Compressa farmaceutica atta a cedere la sostanza attiva in tempi successivi e predeterminabili
US6245351B1 (en) * 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5711691A (en) * 1996-05-13 1998-01-27 Air Packaging Technologies, Inc. Self-closing and self-sealing valve device for use with inflatable structures
US5827535A (en) 1996-06-21 1998-10-27 Banner Pharmacaps, Inc. Graphically impressed softgel and method for making same
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5824338A (en) * 1996-08-19 1998-10-20 L. Perrigo Company Caplet and gelatin covering therefor
US5916881A (en) * 1996-10-07 1999-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo High trehalose content syrup
US5807580A (en) 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
GB9624110D0 (en) * 1996-11-20 1997-01-08 Molins Plc Transferring rod like articles
US5830801A (en) * 1997-01-02 1998-11-03 Motorola, Inc. Resistless methods of gate formation in MOS devices
DE19710213A1 (de) * 1997-03-12 1998-09-17 Basf Ag Verfahren zur Herstellung von festen Kombinationsarzneiformen
US6210710B1 (en) * 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5837301A (en) 1997-04-28 1998-11-17 Husky Injection Molding Systems Ltd. Injection molding machine having a high speed turret
US6149939A (en) * 1997-05-09 2000-11-21 Strumor; Mathew A. Healthful dissolvable oral tablets, and mini-bars
KR100412327B1 (ko) * 1997-07-01 2003-12-31 화이자 인코포레이티드 서트랄린 염 및 서트랄린의 서방성 투여형
AU7904598A (en) 1997-07-09 1999-02-08 Peter Greither Method and device for producing a multi-layer, physiologically tolerated presentation form
US6103260A (en) * 1997-07-17 2000-08-15 Mcneil-Ppc, Inc. Simethicone/anhydrous calcium phosphate compositions
US5942034A (en) * 1997-07-24 1999-08-24 Bayer Corporation Apparatus for the gelatin coating of medicaments
US6110499A (en) 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
DE19733505A1 (de) * 1997-08-01 1999-02-04 Knoll Ag Schnell wirksames Analgeticum
US6602522B1 (en) 1997-11-14 2003-08-05 Andrx Pharmaceuticals L.L.C. Pharmaceutical formulation for acid-labile compounds
DK1035834T3 (da) * 1997-12-05 2002-07-08 Alza Corp Osmotisk doseringsform omfattende en første og anden coating
US6485748B1 (en) * 1997-12-12 2002-11-26 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
KR100775154B1 (ko) 1997-12-19 2007-11-12 스미스클라인 비참 코포레이션 바이트-분산성 정제의 제조 방법
US6432442B1 (en) 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6110500A (en) * 1998-03-25 2000-08-29 Temple University Coated tablet with long term parabolic and zero-order release kinetics
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6365183B1 (en) 1998-05-07 2002-04-02 Alza Corporation Method of fabricating a banded prolonged release active agent dosage form
EP1077065B1 (fr) 1998-05-15 2004-08-04 Chugai Seiyaku Kabushiki Kaisha Preparations a liberation controlee
JP2002516848A (ja) 1998-06-03 2002-06-11 アルザ・コーポレーション 長時間の薬物療法を与える方法および装置
US6106267A (en) * 1998-06-05 2000-08-22 Aylward; John T. Apparatus for forming a compression-molded product
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6103257A (en) * 1998-07-17 2000-08-15 Num-Pop, Inc. System for delivering pharmaceuticals to the buccal mucosa
FR2781152B1 (fr) * 1998-07-20 2001-07-06 Permatec Tech Ag Utilisation d'un polymere de type acrylique en tant qu'agent de desagregation
US6200590B1 (en) 1998-08-10 2001-03-13 Naphcare, Inc. Controlled, phased-release suppository and its method of production
DE19840256A1 (de) 1998-09-03 2000-03-09 Basf Ag Verfahren zur Herstellung von beschichteten festen Dosierungsformen
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
JP3449253B2 (ja) * 1998-10-29 2003-09-22 シオノギクオリカプス株式会社 硬質カプセルの製造方法
US6165512A (en) 1998-10-30 2000-12-26 Fuisz Technologies Ltd. Dosage forms containing taste masked active agents
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6183681B1 (en) * 1998-12-07 2001-02-06 Centurion International, Inc. Multi-stage insert molding method
DE59901613D1 (de) 1999-02-10 2002-07-11 Suwelack Skin & Health Care Ag Beta-1,3-Glucan aus Euglena enthaltendes gefriergetrocknetes Erzeugnis, seine Herstellung und Verwendung
US6274162B1 (en) 2000-01-14 2001-08-14 Bpsi Holdings, Inc. Elegant film coating system
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6248760B1 (en) * 1999-04-14 2001-06-19 Paul C Wilhelmsen Tablet giving rapid release of nicotine for transmucosal administration
JP3716901B2 (ja) * 1999-04-14 2005-11-16 シオノギクオリカプス株式会社 セルロースエーテルフィルム
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
US6375963B1 (en) 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
US20020102309A1 (en) * 1999-09-14 2002-08-01 Jane C. I. Hirsh Controlled release formulation for administration of an anti-inflammatory naphthalene derivative
DE19954420A1 (de) 1999-11-12 2001-05-31 Lohmann Therapie Syst Lts Zubereitung, bestehend aus einer film-, folien- oder oblatenförmigen Darreichungsform mit zweischichtigem Aufbau und integrierter Kennzeichnung
DE19960494A1 (de) * 1999-12-15 2001-06-21 Knoll Ag Vorrichtung und Verfahren zum Herstellen von festen wirkstoffhaltigen Formen
MXPA02006335A (es) * 1999-12-23 2002-12-13 Pfizer Prod Inc Forma de dosificacion de farmaco en capas impulsada por hidrogel.
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
FR2807034B1 (fr) 2000-03-29 2002-06-14 Roquette Freres Mannitol pulverulent et son procede de fabrication
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
GB2362350A (en) 2000-05-11 2001-11-21 Reckitt Benekiser N V Process and press for the production of tablets
US20030086972A1 (en) 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
AU2001288938A1 (en) * 2000-09-07 2002-03-22 Akpharma Inc. Edible candy compositions and methods of using the same
GB0027471D0 (en) * 2000-11-08 2000-12-27 Smithkline Beecham Plc Processes
WO2002066015A1 (fr) 2001-02-16 2002-08-29 Bristol-Myers Squibb Pharma Company Utilisation de polymeres de polyalkylamine dans des dispositifs a liberation regulee
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
KR20040018463A (ko) 2001-07-16 2004-03-03 아스트라제네카 아베 양성자 펌프 억제제 및 제산제를 함유하는 제약 제제
US6558722B2 (en) * 2001-07-18 2003-05-06 Wm. Wrigley Jr. Company Use of powdered gum in making a coating for a confection
GB0120835D0 (en) 2001-08-28 2001-10-17 Smithkline Beecham Plc Process
US6767200B2 (en) * 2001-09-28 2004-07-27 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
CA2446759A1 (fr) 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Formes pharmaceutiques a liberation modifiee
US20040006111A1 (en) 2002-01-25 2004-01-08 Kenneth Widder Transmucosal delivery of proton pump inhibitors
PT1578350E (pt) 2002-03-26 2009-08-27 Euro Celtique Sa Composições revestidas com geles de libertação constante
EP1372040B1 (fr) * 2002-06-11 2008-03-05 ASML Netherlands B.V. Appareil lithographique et méthode pour la fabrication d'un dispositif
TW578439B (en) * 2002-10-25 2004-03-01 Ritdisplay Corp Organic light emitting diode and material applied in the organic light emitting diode
EP1633403A2 (fr) * 2003-05-21 2006-03-15 Control Delivery Systems, Inc. Medicaments combines contenant du diclofenac
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers

Patent Citations (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US582438A (en) * 1897-05-11 John scheidler
US3085942A (en) * 1960-12-28 1963-04-16 Hoffmann La Roche Antitussive compositions and preparation
US3185626A (en) * 1963-03-06 1965-05-25 Sterling Drug Inc Tablet coating method
US3670065A (en) * 1968-06-19 1972-06-13 Karl Gunnar Eriksson Process for producing dosage units of a type resembling tablets
US3726622A (en) * 1971-08-20 1973-04-10 Wolverine Pentronix Compacting apparatus
US3804570A (en) * 1971-11-19 1974-04-16 Werner & Pfleiderer Block press
US4279926A (en) * 1974-03-07 1981-07-21 Spa-Societa Prodotti Antibiotici S.P.A. Method of relieving pain and treating inflammatory conditions in warm-blooded animals
US4139589A (en) * 1975-02-26 1979-02-13 Monique Beringer Process for the manufacture of a multi-zone tablet and tablet manufactured by this process
US4076819A (en) * 1975-05-30 1978-02-28 Parcor Thieno-pyridine derivatives and therapeutic composition containing same
US4218433A (en) * 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4139627A (en) * 1977-10-06 1979-02-13 Beecham Inc. Anesthetic lozenges
US4322449A (en) * 1978-11-15 1982-03-30 Boehringer Ingelheim Gmbh Pharmaceuticals having dotted active ingredients and a method and apparatus for the preparation thereof
US4198390A (en) * 1979-01-31 1980-04-15 Rider Joseph A Simethicone antacid tablet
US4392493A (en) * 1979-09-06 1983-07-12 Dawsonville Corp., N.V. Tattooing apparatus
US4273793A (en) * 1979-10-26 1981-06-16 General Foods Corporation Apparatus and process for the preparation of gasified confectionaries by pressurized injection molding
US4683256A (en) * 1980-11-06 1987-07-28 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4517205A (en) * 1983-01-03 1985-05-14 Nabisco Brands, Inc. Co-deposited two-component hard candy
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4533345A (en) * 1983-06-14 1985-08-06 Fertility & Genetics Associates Uterine catheter
US4569650A (en) * 1984-02-07 1986-02-11 Kilian & Co., Gmbh Tablet press
US4564525A (en) * 1984-03-30 1986-01-14 Mitchell Cheryl R Confection products
US4643894A (en) * 1984-07-24 1987-02-17 Colorcon, Inc. Maltodextrin coating
US4828841A (en) * 1984-07-24 1989-05-09 Colorcon, Inc. Maltodextrin coating
US4725441A (en) * 1984-07-24 1988-02-16 Colorcon, Inc. Maltodextrin coating
US4663147A (en) * 1985-09-03 1987-05-05 International Minerals & Chemical Corp. Disc-like sustained release formulation
US4857330A (en) * 1986-04-17 1989-08-15 Alza Corporation Chlorpheniramine therapy
US4853230A (en) * 1986-04-30 1989-08-01 Aktiebolaget Hassle Pharmaceutical formulations of acid labile substances for oral use
US4816262A (en) * 1986-08-28 1989-03-28 Universite De Montreal Controlled release tablet
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4813818A (en) * 1987-08-25 1989-03-21 Michael Sanzone Apparatus and method for feeding powdered materials
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5004614A (en) * 1988-08-26 1991-04-02 Forum Chemicals Ltd. Controlled release device with an impermeable coating having an orifice for release of drug
US5393533A (en) * 1988-09-09 1995-02-28 The Ronald T. Dodge Company Pharmaceuticals microencapsulated by vapor deposited polymers and method
US4906478A (en) * 1988-12-12 1990-03-06 Valentine Enterprises, Inc. Simethicone/calcium silicate composition
US4984240A (en) * 1988-12-22 1991-01-08 Codex Corporation Distributed switching architecture for communication module redundancy
US5610214A (en) * 1988-12-29 1997-03-11 Deknatel Technology Corporation, Inc. Method for increasing the rate of absorption of polycaprolactone
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5658589A (en) * 1989-04-28 1997-08-19 Mcneil-Ppc, Inc. Subcoated simulated capsule-like medicament
US5275822A (en) * 1989-10-19 1994-01-04 Valentine Enterprises, Inc. Defoaming composition
US4983394A (en) * 1990-05-03 1991-01-08 Warner-Lambert Company Flavor enhancing and medicinal taste masking agent
US5133892A (en) * 1990-10-17 1992-07-28 Lever Brothers Company, Division Of Conopco, Inc. Machine dishwashing detergent tablets
US5538125A (en) * 1990-11-05 1996-07-23 Mcneil-Ppc, Inc. Indexing and feeding systems for apparatus for gelatin coating tablets
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
US5630871A (en) * 1991-01-17 1997-05-20 Berwind Pharmaceutical Services, Inc. Film coatings and film coating compositions based on cellulosic polymers and lactose
US5405642A (en) * 1991-02-27 1995-04-11 Janssen Pharmaceutica N.V. Method of highlighting intagliations in tablets
US5424075A (en) * 1991-03-27 1995-06-13 Miles Inc. Delivery system for enhanced onset and increased potency
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5912013A (en) * 1991-07-23 1999-06-15 Shire Laboratories, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427614A (en) * 1992-02-14 1995-06-27 Warner-Lambert Company Starch based formulations
US5738874A (en) * 1992-09-24 1998-04-14 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates
US5510385A (en) * 1993-06-21 1996-04-23 Zambon Group S.P.A. Pharmaceutical compositions containing the salts of S(+)-2-(4-isobutylphenyl)propionic acid with basic aminoacids
US5641536A (en) * 1993-08-30 1997-06-24 Warner-Lambert Company Tablet coating method
US5871781A (en) * 1993-09-10 1999-02-16 Fuisz Technologies Ltd. Apparatus for making rapidly-dissolving dosage units
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
US5753265A (en) * 1994-07-08 1998-05-19 Astra Aktiebolag Multiple unit pharmaceutical preparation
US6264985B1 (en) * 1994-09-06 2001-07-24 Lts Lohmann Therapie-Systeme Gmbh Laminated tablet with pointed core
US5593696A (en) * 1994-11-21 1997-01-14 Mcneil-Ppc, Inc. Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders
US5626875A (en) * 1995-02-01 1997-05-06 Esteve Quimica, S.A. Stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
US6013281A (en) * 1995-02-09 2000-01-11 Astra Aktiebolag Method of making a pharmaceutical dosage form comprising a proton pump inhibitor
US5627971A (en) * 1995-06-01 1997-05-06 Northern Telecom Limited Machine method for determining the eligibility of links in a network
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US6217902B1 (en) * 1995-06-09 2001-04-17 R. P. Scheier Company Soft gelatin capsules containing particulate material
US6248355B1 (en) * 1995-09-21 2001-06-19 Schwarz Pharma Ag Pharmaceutical composition containing an acid-labile omeprazole and process for its preparation
US6207198B1 (en) * 1995-09-21 2001-03-27 Schwarz Pharma Ag Composition containing an acid-labile omeprazole and process for its preparation
US5861173A (en) * 1995-11-28 1999-01-19 Bayer Aktiengesellschaft Long-lasting release nifedipine preparation
US6183776B1 (en) * 1996-01-08 2001-02-06 Astra Aktiebolag Oral pharmaceutical dosage forms comprising a proton pump inhibitor and an antacid agent or alginate
US6726927B2 (en) * 1997-05-09 2004-04-27 Sage Pharmaceuticals, Inc. Preparation of enteric pharmaceutical dosage forms for omerprazole and lansoprazole
US20020082299A1 (en) * 1997-06-25 2002-06-27 Hans Meyer Method for reducing body weight
US6077541A (en) * 1997-11-14 2000-06-20 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6394094B1 (en) * 1998-05-01 2002-05-28 Enhance Pharmaceuticals, Inc. Method for injection molding manufacture of controlled release devices
US6224910B1 (en) * 1998-05-22 2001-05-01 Bristol-Myers Squibb Company Method for the preparation of an enteric coated high drug load pharmaceutical composition
US6569457B2 (en) * 1998-07-17 2003-05-27 Bristol-Myers Squibb Company Enteric coated pharmaceutical tablet and method of manufacturing
US6730646B1 (en) * 1998-07-29 2004-05-04 Reckitt Benckiser N.V. Composition for use in a dishwasher
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US20010001280A1 (en) * 1998-09-09 2001-05-17 Liang-Chang Dong Dosage form comprising liquid formulation
US6248361B1 (en) * 1999-02-26 2001-06-19 Integ, Ltd. Water-soluble folic acid compositions
US6090401A (en) * 1999-03-31 2000-07-18 Mcneil-Ppc, Inc. Stable foam composition
US6555139B2 (en) * 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US20030060393A1 (en) * 1999-12-29 2003-03-27 Reckitt Benckiser N.V. Composition for use in a dishwasher
US20020051807A1 (en) * 2000-01-13 2002-05-02 Joaquina Faour Osmotic device containing alprazolam and an antipsychotic agent
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US6727200B2 (en) * 2000-08-31 2004-04-27 Mra Laboratories, Inc. High dielectric constant very low fired X7R ceramic capacitor, and powder for making
US20030059466A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Delayed release tablet of venlafaxin
US20030068373A1 (en) * 2001-09-28 2003-04-10 Joseph Luber Immediate release tablet
US20030070903A1 (en) * 2001-09-28 2003-04-17 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20030068367A1 (en) * 2001-09-28 2003-04-10 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20030086973A1 (en) * 2001-09-28 2003-05-08 Sowden Harry S Systems, methods and apparatuses for manufacturing dosage forms
US20030124183A1 (en) * 2001-09-28 2003-07-03 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20030066068A1 (en) * 2001-09-28 2003-04-03 Koninklijke Philips Electronics N.V. Individual recommender database using profiles of others
US6742646B2 (en) * 2001-09-28 2004-06-01 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US6982094B2 (en) * 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165777A1 (en) * 2004-05-21 2006-07-27 Lawrence Solomon Dosage forms contained within a capsule or sachet
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
US20080187581A1 (en) * 2005-03-16 2008-08-07 Subhash Pandurang Gore Delivery System For Mulitple Drugs
US20100239668A1 (en) * 2006-06-19 2010-09-23 Kaplan Allan S Segmented pharmaceutical dosage forms
US8980363B2 (en) * 2007-02-15 2015-03-17 Jagotec Ag Method and apparatus for producing a centred compression coated tablet
US20110014352A1 (en) * 2007-02-15 2011-01-20 Pascal Grenier Method and apparatus for producing a centred compression coated tablet
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
US20100021507A1 (en) * 2007-08-30 2010-01-28 Bunick Frank J Method and Composition for Making an Orally Disintegrating Dosage Form
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8303573B2 (en) 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090192449A1 (en) * 2007-10-23 2009-07-30 Seacrete Llc, A Limited Liability Corporation Of The State Of Delaware Adaptive dispensation in a digestive tract
US8808276B2 (en) 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8109920B2 (en) 2007-10-31 2012-02-07 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090112190A1 (en) * 2007-10-31 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20100016348A1 (en) * 2007-10-31 2010-01-21 Frank Bunick Orally disintegrative dosage form
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US20090112191A1 (en) * 2007-10-31 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8968769B2 (en) 2007-10-31 2015-03-03 Mcneil-Ppc, Inc. Orally disintegrative dosage form
US20090110714A1 (en) * 2007-10-31 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8808271B2 (en) 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090112048A1 (en) * 2007-10-31 2009-04-30 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8707964B2 (en) 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20100016451A1 (en) * 2007-10-31 2010-01-21 Frank Bunick Orally Disintegrative Dosage Form
US8333754B2 (en) 2007-10-31 2012-12-18 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090137866A1 (en) * 2007-11-28 2009-05-28 Searete Llc, A Limited Liability Corporation Of The State Delaware Medical or veterinary digestive tract utilization systems and methods
US20110070301A1 (en) * 2009-09-24 2011-03-24 Luber Joseph R Orally transformable tablets
US8871263B2 (en) 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US20110070304A1 (en) * 2009-09-24 2011-03-24 Kriksunov Leo B Manufacture of tablet having immediate release region and sustained release region
US8343533B2 (en) 2009-09-24 2013-01-01 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US9610224B2 (en) 2009-09-24 2017-04-04 Johnson & Johnson Consumer Inc. Manufacture of tablet in a die utilizing powder blend containing water-containing material
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US20110071185A1 (en) * 2009-09-24 2011-03-24 Bunick Frank J Manufacture of tablet in a die utilizing powder blend containing water-containing material
US8807979B2 (en) 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US20110070170A1 (en) * 2009-09-24 2011-03-24 Koll Gregory E Manufacture of chewing gum product with radiofrequency
US20110071183A1 (en) * 2009-09-24 2011-03-24 Jen-Chi Chen Manufacture of lozenge product with radiofrequency
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US8865204B2 (en) 2009-09-24 2014-10-21 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US8313768B2 (en) * 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US20110068511A1 (en) * 2009-09-24 2011-03-24 Sowden Harry S Machine for the manufacture of dosage forms utilizing radiofrequency energy
US20110071184A1 (en) * 2009-09-24 2011-03-24 Bunick Frank J Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US9107807B2 (en) 2009-09-24 2015-08-18 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9445971B2 (en) * 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US20130292884A1 (en) * 2012-05-01 2013-11-07 Mcneil-Ppc, Inc. Method of manufacturing solid dosage form
JP2017500367A (ja) * 2013-12-23 2017-01-05 ウェン、シャオガンＷＥＮ， Ｘｉａｏｇｕａｎｇ 二層錠剤及びその調製法
US9789066B2 (en) 2014-01-10 2017-10-17 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
US20190076365A1 (en) * 2016-03-15 2019-03-14 Astellas Pharma Inc. Tablet
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles

Also Published As

Publication number Publication date
WO2003026629A3 (fr) 2004-03-04
EP1429742A2 (fr) 2004-06-23
JP2005508325A (ja) 2005-03-31
CA2461616A1 (fr) 2003-04-03
CN1596101A (zh) 2005-03-16
ES2444549T3 (es) 2014-02-25
KR20040037208A (ko) 2004-05-04
EP1429724B1 (fr) 2013-11-06
CN1596100A (zh) 2005-03-16
DE60223269T2 (de) 2008-08-21
WO2003026627A1 (fr) 2003-04-03
US8545887B2 (en) 2013-10-01
CA2446759A1 (fr) 2003-04-03
WO2003026624A9 (fr) 2004-05-06
HUP0401686A3 (en) 2008-04-28
EP1429745A2 (fr) 2004-06-23
CA2461653A1 (fr) 2003-04-03
JP2005508328A (ja) 2005-03-31
MXPA04002981A (es) 2005-06-20
AU2002330164A1 (en) 2003-04-07
ATE404179T1 (de) 2008-08-15
DE60223269D1 (de) 2007-12-13
US20090155372A1 (en) 2009-06-18
KR20040045034A (ko) 2004-05-31
KR20040045031A (ko) 2004-05-31
CA2447984A1 (fr) 2003-04-03
WO2003026616A1 (fr) 2003-04-03
WO2003026629A2 (fr) 2003-04-03
JP2005508329A (ja) 2005-03-31
CN1596102A (zh) 2005-03-16
EP1429743A1 (fr) 2004-06-23
HK1072902A1 (en) 2005-09-16
BR0213593A (pt) 2004-08-31
NZ532096A (en) 2006-10-27
US20040213848A1 (en) 2004-10-28
EP1438018A1 (fr) 2004-07-21
WO2003026628A3 (fr) 2003-05-01
NO20032363L (no) 2003-07-23
US20030219484A1 (en) 2003-11-27
KR20040045026A (ko) 2004-05-31
BR0206061A (pt) 2004-01-13
MXPA04002884A (es) 2005-06-20
CO5570655A2 (es) 2005-10-31
KR20040037207A (ko) 2004-05-04
JP2005529059A (ja) 2005-09-29
CA2461659A1 (fr) 2003-04-03
WO2003026615A2 (fr) 2003-04-03
NO20032362D0 (no) 2003-05-26
ATE376826T1 (de) 2007-11-15
BR0206062A (pt) 2004-01-13
PT1429738E (pt) 2007-12-14
JP2005508326A (ja) 2005-03-31
WO2003026625A9 (fr) 2004-05-06
CA2461354A1 (fr) 2003-04-03
US20040170750A1 (en) 2004-09-02
JP2005509604A (ja) 2005-04-14
KR20040045030A (ko) 2004-05-31
CA2461656A1 (fr) 2003-04-03
ATE476957T1 (de) 2010-08-15
KR20040045032A (ko) 2004-05-31
US20030235616A1 (en) 2003-12-25
KR20040066094A (ko) 2004-07-23
BR0213589A (pt) 2004-08-31
BR0212950A (pt) 2004-10-26
EP1438028A1 (fr) 2004-07-21
CA2461870A1 (fr) 2003-04-03
CN100408029C (zh) 2008-08-06
JP2005508330A (ja) 2005-03-31
MXPA04002980A (es) 2005-06-20
US7972624B2 (en) 2011-07-05
CN1607945A (zh) 2005-04-20
WO2003026626A3 (fr) 2003-10-16
MXPA04002992A (es) 2005-06-20
ES2295427T3 (es) 2008-04-16
HUP0401686A2 (hu) 2004-11-29
BR0213591A (pt) 2004-08-31
EP1429746A2 (fr) 2004-06-23
ES2311073T3 (es) 2009-02-01
MXPA04002979A (es) 2005-06-20
MXPA04002977A (es) 2005-06-20
CN1592611A (zh) 2005-03-09
WO2003026626A2 (fr) 2003-04-03
WO2003026630A1 (fr) 2003-04-03
JP2005535558A (ja) 2005-11-24
MXPA04002891A (es) 2005-06-20
KR20040037206A (ko) 2004-05-04
NZ532568A (en) 2005-07-29
US20030232083A1 (en) 2003-12-18
EP1463489A1 (fr) 2004-10-06
DE60228281D1 (de) 2008-09-25
CA2461684A1 (fr) 2003-04-03
EP1429738B1 (fr) 2007-10-31
NO20032362L (no) 2003-07-14
WO2003026612A3 (fr) 2003-06-26
CN100364515C (zh) 2008-01-30
CN1638740A (zh) 2005-07-13
BR0212951A (pt) 2004-10-26
NO20032364L (no) 2003-07-25
CA2461659C (fr) 2010-12-07
NZ532097A (en) 2006-02-24
EP1429742B1 (fr) 2011-05-04
CN1596104A (zh) 2005-03-16
BR0212921A (pt) 2004-10-13
WO2003026624A1 (fr) 2003-04-03
CA2461865A1 (fr) 2003-04-03
BR0206086A (pt) 2003-12-23
CN1592612A (zh) 2005-03-09
EP1429737A1 (fr) 2004-06-23
KR20040037203A (ko) 2004-05-04
KR20040045033A (ko) 2004-05-31
US20040241208A1 (en) 2004-12-02
JP2005508327A (ja) 2005-03-31
WO2003026612A2 (fr) 2003-04-03
WO2003026628A2 (fr) 2003-04-03
EP1432404A1 (fr) 2004-06-30
EP1438018B1 (fr) 2010-08-11
BR0213588A (pt) 2004-08-31
US20040062804A1 (en) 2004-04-01
BR0212946A (pt) 2004-10-26
US20040213849A1 (en) 2004-10-28
MXPA04002976A (es) 2005-06-20
US20040018327A1 (en) 2004-01-29
US7968120B2 (en) 2011-06-28
CA2461354C (fr) 2010-04-27
WO2003026614A9 (fr) 2004-02-26
EP1429738A2 (fr) 2004-06-23
US20050266084A1 (en) 2005-12-01
CN1592610A (zh) 2005-03-09
JP2005511515A (ja) 2005-04-28
CN1592613A (zh) 2005-03-09
EP1429724A1 (fr) 2004-06-23
ATE507823T1 (de) 2011-05-15
DE60237294D1 (de) 2010-09-23
MXPA04002974A (es) 2005-06-20
NO20041613L (no) 2004-04-20
NO20032364D0 (no) 2003-05-26
WO2003026613A1 (fr) 2003-04-03
MXPA04002975A (es) 2005-06-20
JP2005509605A (ja) 2005-04-14
WO2003026614A1 (fr) 2003-04-03
PL369134A1 (en) 2005-04-18
US20030232082A1 (en) 2003-12-18
EP1429746B1 (fr) 2008-08-13
CA2446760A1 (fr) 2003-04-03
CA2461682A1 (fr) 2003-04-03
US20040241236A1 (en) 2004-12-02
US7635490B2 (en) 2009-12-22
MXPA04002973A (es) 2005-06-20
US20080305150A1 (en) 2008-12-11
NO20032363D0 (no) 2003-05-26
WO2003026625A1 (fr) 2003-04-03
DE60239945D1 (de) 2011-06-16
MXPA04002978A (es) 2005-06-20
WO2003026615A3 (fr) 2003-07-31
EP1438030A2 (fr) 2004-07-21
US7416738B2 (en) 2008-08-26

Similar Documents

Publication Publication Date Title
US7807197B2 (en) Composite dosage forms having an inlaid portion
US20050019407A1 (en) Composite dosage forms
EP1811971B1 (fr) Formes de doses possedant une surface a micro reliefs et procede et appareil de production de celles-ci
US20040146559A1 (en) Dosage forms having an inner core and outer shell with different shapes
ZA200403166B (en) Dosage forms having an inner core and outer shell with different shapes.
EP1809258B1 (fr) Formes posologiques a surface a microrelief et procedes et appareil d'obtention de celles-ci
US20070281022A1 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
EP1811970B1 (fr) Forme posologique avec surface a microreliefs et procede et dispositif de fabrication
US20070224258A1 (en) Dosage forms having a randomized coating
EP1811968B1 (fr) Formes posologiques comprenant une surface a microrelief et leurs procedes et dispositifs de production
EP1809256B1 (fr) Formes posologiques a surface en microrelief et procedes et appareil d'obtention de celles-ci
US20060088587A1 (en) Dosage forms having a microreliefed surface and methods and apparatus for their production
AU2002337783A1 (en) Dosage forms having an inner core and outer shell with different shapes
AU2002334735A1 (en) Dosage forms having an inner core and outer shell

Legal Events

Date Code Title Description
AS Assignment

Owner name: MCNEIL-PPC, INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SOWDEN, HARRY S.;BUNICK, FRANK J.;MCNALLY, GERARD P.;AND OTHERS;REEL/FRAME:015454/0001;SIGNING DATES FROM 20040511 TO 20040603

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION